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Abstract 
 
While investigating methylcytosine content in Purkinjie neurons in 2009, researchers 
uncovered a previously forgotten base, 5-hydroxymethylcytosine (5hmC) in high 
concentrations. Since then, 5hmC has been found in various tissue types and has been 
implicated in biological processes such as development, gene regulation, DNA demethylation 
and tumorigenesis, leading researchers to conclude that 5hmC could be an epigenetic mark.  
 
The lab where this research was conducted has previously studied methylcytosine in a cohort 
of monozygotic twins discordant for psoriasis, and in this project we aimed to do the same, 
only this time focusing on 5hmC. Unfortunately, due to technical hurdles, time did not allow 
study of 5hmC levels in the discordant twins. We were however able to show the presence of 
5hmC in both mouse brain and a subset of monozygotic control twins using an ELISA assay. 
Furthermore, we demonstrated a novel genome-wide method to examine 5hmC at a subset of 
CpG dinucleotides, through the combined use of Zymo Research Corporation´s Quest 5hmC 
Detection Kit, appropriate size selection and high-throughput-sequencing. 
 
Using this novel method, we were able to identify a small number of differentially 
hydroxymethylated peaks in our twin samples using MACS (Model-based analysis for ChIP-
seq). Further sequencing to achieve a greater read depth is required to fully validate the 
method, but the method could conceivably now be applied towards the original goal of 
finding sites of differential hydroxymethylation in monozygotic twins discordant for 
Psoriasis. 
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1 Introduction 
1.1 5-hydroxymethylcytosine 
5-hydroxymethylcytosine (5hmC) was first described in 1952 as being the sole cytosine base 
of bacteriophage T2 (Hershey and Chase 1952). Later, it was found in T4 bacteriophage, and 
shown to protect progeny phage DNA from degradation by host nuclease activity, which can 
degrade unmodified cytosines (Wiberg 1967). 5hmC was then found in mammalian brain and 
liver tissue (Penn, Suwalski et al. 1972), but until recently, its function hasn’t been further 
researched in mammals due to technological limitations. While comparing the abundance of 
5mC in Purkinje and granule cell nuclei, 5hmC was identified in mouse cerebellar DNA, as 
well as in many other tissue types, but at much lower concentrations. At the same time it was 
concluded that 5hmC could possibly be an epigenetic mark. (Kriaucionis and Heintz 2009).   
 
5hmC has been found in its highest concentrations in the brain followed by breast and liver    
(Branco, Ficz et al. 2012). It is also present throughout all the other tissues in the body; and it 
was found that tissue type, not correlation to 5mC or TET expression (the enzymes 
responsible for 5hmC synthesis), predicts 5hmC concentration (Nestor, Ottaviano et al. 
2012). However, locus specific enrichment is commonly found at the H19/IGF2 and HOXA 
loci.  
  
 
 
Figure 1: Structures of C, 5mC and 5hmC (Szulwach, Li et al. 2011) 
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1.1.1  Biological Pathways  
5-hydroxymyethylcytosine is a further modified version of 5-methylcytosine; it contains a 
hydroxyl group connected to the methyl group at position 5 on the pyrimidine ring (Figure 1). 
Oxidation of the methyl group on 5mC converts it to 5hmC, and has been found to be 
facilitated by Ten-eleven translocation 1-3 (TET 1-3) proteins (Tahiliani, Koh et al. 2009; Ito, 
D'Alessio et al. 2010). The TET 1-3 family of proteins are 2-oxoglutarate (2OG) and Fe (II)-
dependent dioxygenase enzymes, all of which have the capacity to catalyze the conversion of 
5mC to 5hmC. They are also able to further oxidize 5hmC to 5-formylcytosine (5-fC), and 5-
carboxycytosine (5-caC) (He, Li et al. 2011) (Figure 2).  
 
 
 
Figure 2: Proposed models of passive and active DNA demethylation (Wu and Zhang 2011) 
 
All TET proteins contain a cysteine-rich region, a double-stranded β-helix fold, and a CXXC 
domain (Figure 3) – a DNA binding domain that has been shown to be a CpG-binding motif, 
and is likely involved in the recruitment of TET proteins to DNA (Szwagierczak, Bultmann 
et al. 2010). TET1 has been shown to mainly bind to gene rich regions of the genome, 
showing a preference for transcription start sites (TSSs). It has also been found to bind to 
CpG islands and bivalent promoters (ones simultaneously marked with both activating and 
repressing modifications) in mouse embryonic stem (ES) cells, consistent with the significant 
enrichment of 5hmC, but not 5mC at bivalent promoters (Matarese, Carrillo-de Santa Pau et 
al. 2011). TET1 binding also shows a near-perfect overlap with DNAse-1 hypersensitive sites 
found in ES cells – possibly providing evidence for activity of TET1 in transcriptional 
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regulation (Levasseur, Wang et al. 2008). Though TET1 is the primary enzyme for oxidation 
of 5mC to 5-fC, the other TET proteins, TET2 and TET3 are able to compensate for loss of 
TET1. The knockout of TET1 in ES cells leads to a slight reduction of 5hmC levels, but due 
to the compensatory action of TET2, pluripotency is not affected (Wossidlo, Nakamura et al. 
2011). Similarly, TET3 has been shown to convert 5mC to 5hmC in the paternal pronucleus 
of mice (He, Li et al. 2011). Whereas TET proteins have distinct non-redundant roles in 
meiosis (Tan and Manley 2009), it is still unclear as to whether or not they have a redundant 
role in regards to 5hmC synthesis and further oxidation to 5-fC. 
 
 
Figure 3: Conserved domains of TET proteins (Williams, Christensen et al. 2012) 
 
Evidence suggests that both passive and active DNA demethylation may be facilitated by the 
oxidation of 5mC to 5hmC by TET proteins, as this can alter both global and locus-specific 
levels of 5mC (Wu and Zhang 2011). Proteins containing methyl-binding domains (MBD), 
such as methyl-CpG-binding protein 2 (MeCP2), and Dnmt1 (DNA methyltransferase) are 
unable to recognize 5hmC (Valinluck, Tsai et al. 2004; Valinluck and Sowers 2007; Jin, 
Kadam et al. 2010). Thus, when encountering a 5hmC instead of 5mC, Dnmt1 will be unable 
to maintain existing methylation patterns, leading to passive DNA demethylation. Though it 
is still unclear how 5hmC leads to active demethylation, multiple models have been 
proposed. The model with the most support proposes that oxidation of 5mC to 5hmC and 
further oxidation to 5fC and 5caC is followed by base excision repair (BER). This model is 
supported by data showing that Thymine DNA glycosylase (TDG) can efficiently remove 
5fC and 5caC at CpG sites, and subsequent base repair introduces an unmodified cytosine 
(Maiti and Drohat 2011). Additional support for this model comes from the finding that loss 
of TDG in mice leads to elevated levels of methylation, and subsequent death (Cortellino, Xu 
et al. 2011). Moreover, the DNA methyltransferases Dnmt3a and Dnmt3b have been shown 
to have DNA dehydroxymethylase activity (Chen, Wang et al. 2012). A recent study of 
primordial germ cells showed that repression of Dnmt3a/Dnmt3b led to the prevention of re-
methylation, thereby allowing the seemingly functionally redundant TET1/2 to further 
oxidate 5mC to 5hmC (Hackett, Sengupta et al. 2013).  
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To gain more insight on how TET1 and 5hmC affect transcription, multiple laboratories have 
mapped the genome-wide occupancy of TET1 in mouse ES cells (Williams, Christensen et al. 
2011; Wu and Zhang 2011; Xu, Wu et al. 2011), and a comparison of all the data sets showed 
that 90% of the TET1 target genes overlap (Wu and Zhang 2011). In these datasets, it was 
shown that TET1 binds preferentially to CpG islands, and gene rich regions at TSSs and 
promoter regions, all of which have a high concentration of 5hmC. Gene promoters 
associated with bivalent domains that bear H3K4me3 and H3K27me3 marks are associated 
with both TET1 and 5hmC (Pastor, Pape et al. 2011). 5hmC was shown to be enriched at 
gene bodies of highly transcribed genes and at the promoters of PRC2-repressed genes (Ficz, 
Branco et al. 2011), supporting the possibility of it having a role in both transcriptional 
activation and repression. A recent study has proposed that when 5hmC is located in 
promoters it has an inhibitory role in regards to transcription, but when in the gene body, it 
has a neutral effect (Robertson, Robertson et al. 2011). There is a great deal of data showing 
that 5hmC is involved in regulation of transcription, but the mechanisms have not been 
clearly elucidated.  
 
1.1.2 5-hydroxymethylcytosine and Development 
While the status of DNA methylation during development is now well known, the role of 
5hmC during development is still unclear. 5hmC has been shown to accumulate in the 
paternal pronucleus of mice, coinciding with the loss of 5mC (Iqbal, Jin et al. 2011) (Figure 
4). The same data has also been found in both rabbit and bovine zygotes (Wossidlo, 
Nakamura et al. 2011); suggesting that 5hmC plays a role in DNA demethylation during 
zygote development.  
 
TET3 has been shown to be expressed at high levels in oocytes and zygotes, but not in later 
stages of development (Figure 4). Knockdown or siRNA-mediated down-regulation of TET3 
in female zygotes has been shown to block the oxidation of 5mC to 5hmC and leads to 
reduced developmental fitness and fetal survival (Gu, Guo et al. 2011), providing further 
evidence that oxidation of 5mC is an important event during development.  
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Figure 4: TET3 expression and amount of 5mC/5hmC present during development (Wu and Zhang 2011)  
 
In the blastocyst stage of development in mouse zygotes, both TET1 and 5hmC are abundant 
(Ito, D'Alessio et al. 2010), but knockdown of TET1 still leads to differentiation of mouse ES 
cells, and TET1 null mutant ES cells are still able to proliferate under normal cell culture 
conditions (Dawlaty, Ganz et al. 2011). Because TET1 binds to numerous gene promoters of 
ES cell transcription factors, it is likely that TET1 is involved in the regulation of 
pluripotency (Wu and Zhang 2011). An RNA-seq analysis has confirmed that a TET1 and 
TET2 double knockdown in mouse ES cells led to down-regulation of several pluripotency 
factors (Ficz, Branco et al. 2011). However, other studies have shown that knockdown of 
TET1/TET2 do not affect pluripotency (Koh, Yabuuchi et al. 2011; Williams, Christensen et 
al. 2011). These discrepancies lead to an unclear understanding of the role of TET1 in 
development and pluripotency, though there may be other mechanisms that compensate for 
the loss of TET1/TET2 (Hackett, Sengupta et al. 2012).  
 
As 5hmC is found in its highest concentrations in brain tissue, it is apparent that 5hmC must 
play a role in neurodevelopment (Nestor, Ottaviano et al. 2012). Enrichment of 5hmC at gene 
bodies has been shown to be positively correlated with gene expression in the frontal lobe 
tissue of the human brain (Jin, Wu et al. 2011). Purkinjie neurons, which are considered to be 
a primary organizer in the human brain, contain a greater amount of 5hmC than other 
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neurons, providing evidence for its function in neurodevelopment, and its disregulation may 
contribute to the pathogenesis of neurodevelopmental disorders (Wang, Pan et al. 2012).  
 
1.1.3 5-hydroxymethylcytosine in Disease 
Hypermethylation of promoters is an epigenetic hallmark of many types of cancer. It leads to 
the silencing of tumor suppressor genes, thereby enabling cancer proliferation (Jones and 
Laird 1999). DNA methyltransferases (DNMTs), which catalyze DNA methylation, have 
been correlated to poor prognosis in human cancers when their activity is increased.  
 
 Whereas deregulation of DNA methylation leading to abnormal gene expression is common 
in cancer, hydroxymethylation is always decreased (Kinney and Pradhan 2013), though its 
biological significance is still unknown.  Decrease in hydroxymethylation is most likely due 
to loss of activity of TET enzymes. It has been reported that a loss-of-function mutation in 
the TET2 gene leads to myeloid malignancies; suggesting that compromised DNA 
demethylation can play a role in tumorigenesis (Kudo, Tateishi et al. 2012).  Solid tumors 
have also been shown to have lower 5hmC levels than normal tissues (Haffner, Chaux et al. 
2011).  
 
Using mammalian cells, it was shown that TET1 expression was decreased in 50% of 
colorectal cancers, and 73% of the tumors investigated had a reduced level of 5hmC in 
comparison to neighboring tissues.  Reduced TET1 expression was also shown to be tightly 
associated with a decrease of TET3 mRNA.  88% of tumors that showed no TET1 gene 
regulation showed increased expression of DNMT genes. It is likely that the suppression of 
TET1, as well as upregulation of DNMT1 affects the amount of 5hmC in cancerous tumors 
(Kudo, Tateishi et al. 2012).  
 
Along with its disregulation in tumorigenesis, TET2 mutations have been identified in B- and 
T-cell lymphoma (Quivoron, Couronne et al. 2011), and are primarily associated with a state 
of DNA hypermethylation, and low 5hmC levels (Figueroa, Abdel-Wahab et al. 2010). As 
seen in acute myeloid leukemia (AML), the function of TET2 can also be inhibited by 
IDH1/2 mutations, which produce 2-hydroxyglutarate (2-HG) and compete with TET2’s 
substrate 2-OG (Cimmino, Abdel-Wahab et al. 2011). Both TET2 mutations and IDH1/2 
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mutations prevent oxidation of 5mC and lead to an increase in global 5mC levels (Figure 5) 
(Dang, White et al. 2009; Figueroa, Abdel-Wahab et al. 2010; Gross, Cairns et al. 2010).  
 
 
Figure 5: Both TET2 and IDH1/2 mutations lead to loss of 5hmC in AML, but are not seen to occur 
simultaneously (Cimmino, Abdel-Wahab et al. 2011).  
 
Based on these studies it can be concluded that a global decrease in 5hmC can be accepted as 
a characteristic of malignancies, and that low levels of 5hmC encourage the emergence of 
both cancerous cells and solid tumors (Delhommeau, Dupont et al. 2009).  Reduction of 
5hmC may also be enhanced by active growth of cancer cells, possibly due to the activity of 
the maintenance of 5mC catalyzed by DNMT1(Valinluck and Sowers 2007; Inoue and Zhang 
2011).  As 5hmC is implicated as an intermediate in DNA demethylation, the loss of 5hmC in 
cancers may in fact lead to the increase in methylation that is seen in many types of cancer. 
 
 
1.2 Epigenetics 
Epigenetics has been defined as “heritable changes in gene expression that occur without a 
change in DNA sequence” (Wolffe and Matzke 1999), and is most prominently seen via 
DNA methylation and chromatin modifications. On a molecular level, DNA 
methyltransferases, methyl-CpG-binding proteins, chromatin remodeling factors, histone-
modifying enzymes, chromosomal proteins and transcriptional factors all act together to 
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create the epigenetic landscape (Nakao 2001). Epigenetic states of daughter cells are 
inherited from their parent cells during DNA replication and cell division, thus showing that 
the epigenetic state is retained throughout the cell cycle (Rakyan, Preis et al. 2001; Groth, 
Rocha et al. 2007).  
 
DNA methylation is the best-characterized chemical modification of DNA; in mammals, 
nearly all methylation is found on CpG dinucleotides, and areas with high CpG density, 
termed CpG islands. Methylation of CpG islands is associated with transcriptional repression 
(Goll and Bestor 2005).  Somatic cells are able to maintain and pass on their epigenetic 
profiles, while germline cells are reprogrammed during development. The enzymes 
responsible for DNA methylation are called DNA methyltransferases (DNMTs), and are 
classified into two groups: maintenance methyltransferases, which add methyl groups to 
hemimethylated DNA during replication, and de novo methylases, which add methyl groups 
after replication (Bestor 2000). DNA methylation also plays a role in formation of 
heterochromatin, X chromosome inactivation, and mammalian imprinting (Yang and Kuroda 
2007).  
 
Chromatin structure can be influenced by covalent histone modifications, and is able to 
influence gene expression patterns (Jenuwein and Allis 2001). The ‘histone code’ (Figure 6) 
refers to the numerous different modifications found on histone tails such as acetylation, 
phosphorylation, methylation, ubiquitilation and more. These modifications in single or 
combinations will lead to changes in gene expression such as transcriptional activation or 
repression (Strahl and Allis 2000). Interestingly, 5hmC was found to be enriched at enhancers 
containing H3K4me1 marks, but not at active enhancers containing H3K27Ac marks, 
suggesting that 5hmC may also lead to an open chromatin state (Sun, Jolyon et al. 2013).   
 
 
Figure 6: Possible modifications on H3 tail (Sims and Reinberg 2008) The different modifications are indicated 
as following: P – phosphorylation, orange; Ac – acetylation, blue; Me – methylation, green indicates an 
activating mark, red indicates a repressive mark, black indicates a mark not associated with transcription.  
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Noncoding RNAs (ncRNAs) are also involved in epigenetic phenomena. For example, 
ncRNA Xist regulates X-chromosome inactivation in females (Mikkelsen, Wakefield et al. 
2007), and several genes are subject to post-transcriptional gene silencing by miRNAs 
(Wiklund, Kjems et al. 2010). Interestingly, while DNA methylation and histone 
modifications occur before gene transcription, ncRNAs can act both prior to and after 
transcription.  
 
1.2.1 Epigenetics & Development 
Mammalian development is characterized by many epigenetic events, the first being active 
demethylation of the paternal genome, taking place in the zygote (Mayer, Niveleau et al. 
2000). Demethylation continues throughout the first few early embryonic replication cycles, 
though this may be a passive event due to Dnmt1 moving from the nucleus to the cytoplasm 
(Carlson, Page et al. 1992). The active demethylation does not remove all methyl groups, as 
DMRs (differentially methylated regions) at imprinting centers and other specific regions are 
able to conserve their methylation status (Bourc'his, Xu et al. 2001; Smallwood, Tomizawa et 
al. 2011).  
 
Around the time of embryo implantation, Dnmt3a and Dnmt3b are present in high 
concentrations, concurrent with a dramatic increase in genome-wide methylation. Some 
sequences can become up to 80% methylated, though CpG islands remain unmethylated 
(Okano, Bell et al. 1999; Laurent, Wong et al. 2010). CpG islands are most likely protected 
from methylation by Sp1 motifs, which also have the ability to protect sequences not located 
in CpG islands, as shown after being introduced as a transgene in one-cell embryos 
(Brandeis, Frank et al. 1994; Siegfried, Eden et al. 1999).  
 
After implantation, additional changes occur in methylation, most notably the silencing of the 
pluripotency genes Oct-3/4 and Nanog, allowing embryonic differentiation to proceed 
(Scholer 1991). The pluripotency genes are turned off first through a repression-factor 
mechanism, followed by recruitment of the histone methyltransferase G9a to their promoters, 
facilitation histone deacetylation, with subsequent methylation of H3K9, which binds HP1, 
forming heterochromatin (Feldman, Gerson et al. 2006; Cedar and Bergman 2012). The G9a 
complex is also able to recruit Dnmt3a/b, leading to the methylation of pluripotency gene 
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promoters (Epsztejn-Litman, Feldman et al. 2008). Thus, the pluripotency genes become 
permanently silenced.  
 
In females, inactivation of the second X chromosome is a major epigenetic event, and 
inactivation occurs in a multi-stage process, beginning with the expression of Xist, a non-
coding gene exclusively expressed from the inactive X chromosome (Keohane, O'Neill L et 
al. 1996). Eventually, Xist RNA coats the entire inactive X chromosome, and recruits 
silencing factors to keep it repressed (Jeon, Sarma et al. 2012). Histone methylases are 
responsible for generating heterochromatin and recruiting Dnmts that methylate CpG island 
promoters, which occurs several days after the initial X-inactivation (Cedar and Bergman 
2009).  
 
Tissue-specific genes that have been silenced through methylation at the beginning of 
development must be unmethylated for development to proceed. The genes must be 
recognized by cell-type-specific factors that must recruit the appropriate molecules to 
demethylated their promoters (Yisraeli, Adelstein et al. 1986). Tissue-specific de-novo 
methylation of previously protected sequences in CpG islands also occurs, though these 
regions are not associated with promoters, but with coding regions, where methylation is 
associated with gene activation (Straussman, Nejman et al. 2009).  
 
1.2.2 Epigenetics & Disease 
Diseases such as cancer, developmental disorders, and autoimmune disorders can be 
characterized by epigenetic abnormalities. While most of the focus lies on DNA methylation; 
other factors such as chromatin remodeling, histone modifications and non-coding RNAs are 
also implicated in many diseases.  
 
A representative epigenetic characteristic of cancer is a global loss of 20-60% of DNA 
methylation in concurrence with hypermethylation at specific promoters at CpG islands 
(Goelz, Vogelstein et al. 1985). Hypomethylation occurs most frequently at repetitive 
sequences, leading to translocations, chromosomal instability and disruption of gene 
expression; which can lead to abnormal expression of oncogenes (Eden, Gaudet et al. 2003). 
Hypermethylation of promoters leads to disruption of genes associated with DNA repair, 
vitamin response, Ras signaling, cell cycle control, the p53 network, and apoptosis (Esteller 
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2007). miRNAs, which are downregulated in cancer, are hypermethylated at their promoters, 
which is also linked to metastasis development (Lujambio, Calin et al. 2008).  
 
Epigenetic factors are significant players in key steps of nervous system development, 
specifically when neural cells lose their multipotency (Yoo, Staahl et al. 2009). Point 
mutations in the MBD protein MeCP2 lead to Rett Syndrome, a neurodevelopmental disorder 
leading to regression of motor and language skills after apparently normal development for 
the first 6-18 months after birth (Zachariah and Rastegar 2012).  
 
Autoimmune disease results from the loss of immune tolerance to self-specific antigens 
(Portela and Esteller 2010). Immunodeficiency-Centromeric Instability (ICF) syndrome, one 
of the most well known autoimmune diseases is caused by mutations in DNMT3B, leading to 
extreme immunodeficiency from defective Dnmt3b enzyme activity (Robertson 2005). Most 
autoimmune diseases are not due to loss of functioning methylases; instead, they stem from 
hypomethylation of immune-related genes. Such is the case for systemic lupus 
erythematosus, where hypomethylation is found in the PRF1, CD70, CD154 and IFGNR2 
genes, and also in the rRNA gene promoter 18S and 28S. miRNAs are also shown to mediate 
progression of systemic lupus erythematosus; miR-21 and miR-148a target DNMT1 and 
contribute to DNA hypomethylation (Pan, Zhu et al. 2010).  
 
1.2.3 Epigenetics & Psoriasis 
Psoriasis is a chronic T-cell-mediated disease of the skin occurring equally in men and 
women; approximately 2% of the population is affected. It is characterized by erythematous 
plaques, often covered by a silvery scaling, and enhanced keratinocyte proliferation (Wrone-
Smith and Nickoloff 1996; Nickoloff and Nestle 2004). There is evidence suggesting that 
psoriasis has a genetically heritable component, and there are several genes that have been 
linked to the disease.  There are also several environmental triggers associated with the 
pathogenesis of psoriasis, leading to the hypothesis that epigenetic factors also play a role in 
disease proliferation. These triggers include trauma, infections, drugs, smoking and alcohol 
consumption. (Zhang, Su et al. 2012) 
 
Aberrant DNA methylation has been seen to disrupt gene expression, and this phenomenon 
has been seen in psoriasis. Both the p15 and p21 genes have been found to be 
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hypomethylated in individuals with psoriasis (Zhang, Zhang et al. 2009).  A previous study 
using monozygotic twins discordant for psoriasis showed that changes in gene expression for 
a large number of immune response related genes (LDHC, IL13, TNFSF11, and more) were 
correlated to changes in methylation status of the gene (Gervin, Vigeland et al. 2012). 
Another example of atypical DNA methylation in psoriasis involves the SHP-1 promoter 2 
region; SHP-1 regulates growth and proliferation processes in skin, and has been found to be 
extensively demethylated at the promoter 2 region in keratinocytes from psoriatic lesions 
(Ruchusatsawat, Wongpiyabovorn et al. 2006).  
 
In addition to irregularities in DNA methylation, histone modifications and miRNA 
aberrations are also implicated in psoriasis. Histone deacetylase 1 (HDAC-1) has been shown 
to be overexpressed in psoriatic tissues, and HDAC SIRT1 (silent mating type information 
regulation 2 homologue 1) may prevent normal proliferation of keratinocytes (Tovar-Castillo, 
Cancino-Diaz et al. 2007; Blander, Bhimavarapu et al. 2009). A miRNA that can activate 
inflammatory cytokines – miR203 has been found to be overexpressed in patients with 
psoriasis (Sonkoly, Wei et al. 2007).  
 
These results support the notion that epigenetic disregulation of genes related to the immune 
system can lead to autoimmune disease proliferation. There is currently no research on 5hmC 
in regards to any type of autoimmune disease, most likely due to the relative newness of 
5hmC research.  
 
1.3 Twin Studies 
In comparison to dizygotic (DZ) twins who only share half of their DNA, monozygotic (MZ) 
twins, which account for 1 in 250 live births, share the same DNA sequence, (Hall 1996). 
Division of the zygote is not hereditary and is seen as abnormal (Ballestar 2010). 
Interestingly, both MZ and DZ twins exhibit phenotypic differences. In DZ twins this can be 
attributed to genetic differences, while phenotypic differences in MZ twins can be attributed 
to environment (Petronis 2006).  This makes MZ twins the ideal model for researching 
environmental epigenetics, as the abundance of differences such as single-nucleotide 
polymorphisms (SNPs) found in DZ twins interfere with analysis.   
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MZ twins are identical in their DNA profiles, and their epigenetic profiles can provide insight 
into phenotypic differences. In a previous twin study of a group of 40 twin pairs ranging in 
age from 3-74 years, it was found that 65% of the MZ twins had nearly identical global 5mC 
levels and acetylation of histones H3 and H4 (Fraga, Ballestar et al. 2005). However, the 
other 35% had significant differences in their epigenetic profiles; interestingly enough, this 
group was comprised of the older twin pairs, suggesting that older twin pairs have greater 
epigenetic differences than younger ones. It was also observed that the older twins pairs had 
up to 2.5 times as many 5mC differences in CpG islands, and the result of a gene expression 
microarray analysis also showed that there were four times as many differentially expressed 
genes in the older twin pairs than the younger (Fraga, Ballestar et al. 2005).  Later studies 
have confirmed that changes in methylated status are due to aging; age-related locus specific 
variation in methylation has been shown in multiple tissues in twins (Rakyan, Down et al. 
2010). Thus, the importance of age must be taken into consideration when studying 
epigenetics both in twins and individuals.  
 
Twin cohorts are fundamental in human studies, as using MZ twins makes comparison of 
phenotypic concordance easy to estimate heritability and identify disease specific genes, as 
well as being a powerful indicator of the influence of environmental factors on phenotype 
(Ballestar 2010). Disease concordance can be expressed as either pairwise or probandwise 
concordance, where pairwise concordance is the proportion of the affected twin pairs 
concordant for disease (e.g. 30 of 100 pairs are affected, resulting in 30% concordance); 
probandwise concordance estimates the risk of a twin developing a disease if the co-twin has 
already been diagnosed (Bogdanos, Smyk et al. 2012). A high rate of concordance presumes 
a predominant genetic influence, whereas low concordance rate is assumed to be due to 
environmental factors. The concordance rates of many autoimmune diseases have been 
studied in MZ twins; Type I diabetes has been found to have a concordance rate of between 
13-47.4% (Kaprio, Tuomilehto et al. 1992; Matsuda and Kuzuya 1994), 60-75% for Coeliac 
disease (Bardella, Fredella et al. 2000; Greco, Romino et al. 2002), and between 35 and 65% 
in Psoriasis (Brandrup, Hauge et al. 1978; Duffy, Spelman et al. 1993).  
 
Though there is a high concordance for many types of heritable disease in MZ twins, rates of 
discordance can also be very high, generally over 50%, implying that epigenetics is an 
important contributing factor to the discordant phenotype (Kendler and Prescott 1999; 
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MacGregor, Snieder et al. 2000).  Discordance rates increase inversely with disease 
prevalence, where discordance is calculated as a function of prevalence. The discordant MZ 
twin model is a robust tool that is able to detect phenotypic risk factors while controlling for 
unknown confounding variables (Bell and Spector 2011).  For example, schizophrenia and 
rheumatoid arthritis have been found to have a discordance rate of about 80%, while only 
being present in 1% of the population (MacGregor, Snieder et al. 2000; Sullivan, Kendler et 
al. 2003). However, osteoarthritis has a discordance rate of about 40%, and a prevalence of 
20% (Spector, Cicuttini et al. 1996).  
 
Epigenetic studies in MZ discordant twins can be used to identify differences in the 
epigenetic profiles of co-twins, to identify disease specific genes. In a previous discordant 
MZ twin study looking at schizophrenia, it was found that there were greater differences in 
methylation of the dopamine D2 receptor gene (DRD2) between the discordant twins than in 
unrelated cases (Petronis, Gottesman et al. 2003). Subsequent studies have found phenotype-
related methylation changes in discordant MZ twins in bipolar disorder (Kuratomi, Iwamoto 
et al. 2008), caudal duplication anomaly (Oates, van Vliet et al. 2006), and the catechol-O-
methyltransferase gene (Mill, Dempster et al. 2006).  
 
1.4 Investigating 5-hydroxymethylcytosine 
There are an increasing number of methods using to investigate 5hmC as it has only recently 
become of interest to researchers again. Methods such as Mass Spectrometry, High-
Performance Liquid Chromatography, and ELISA assays (Section 2.1) can be used to 
quantify and locate 5hmC on a global level. Sequence-specific detection of 5hmC has proven 
to be more difficult, but one is able to locate 5hmC at a single base resolution using methods 
such as hMeDIP-seq, CMS or GLIB followed by DNA sequencing, selective chemical 
labeling, Ox-BS-Seq and TAB-seq. (Kriaucionis and Heintz 2009).  
 
1.4.1 Isolation and Enrichment of  5hmC 
Several methods rely on the specific recognition of 5hmC by antibodies, which offer the 
advantage of requiring little specialized lab equipment.  However, there are two big 
disadvantages stemming from the usage of antibodies themselves, first being the fact that the 
antibodies may cross react with either unmodified or methylated cytosine bases, and 
secondly, antibodies are specific for regions highly enriched with 5hmC, thereby being less 
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likely to capture regions with few 5hmC bases. hMeDIP (Hydroxymethylated DNA 
Immunoprecipitation) is comparable to the older and more widely practiced MeDIP 
(Sorensen and Collas 2009). There exist already several commercial suppliers of kits to 
perform hMeDIP, though the results generally have only moderate resolution and give only 
relative quantification information (Booth, Branco et al. 2012).   
 
Chemically modifying 5hmC bases before pull-down is another method of isolating 
fragments containing 5hmC. GLIB involves transferring glucose molecules to 5hmC via T4 
phage β-glucosyltransferase, with subsequent oxidation using sodium periodate and further 
chemical modification yielding two biotin molecules at each 5hmC site, allowing pull-down 
using streptavidin beads. Another type of chemical modification of 5hmC yields 5-
methylenesulfonate (CMS) from sodium bisulfite conversion, followed by 
immunoprecipitation of CMS-containing DNA with an antibody specific to CMS (Pastor, 
Pape et al. 2011). 
 
DNA isolated and enriched using the above methods can be subject to a number of 
downstream applications such as qPCR (Section 2.5), Microarray Analysis, and Next 
Generation Sequencing.  
 
1.4.2 Direct detection of 5-hydroxymethylcytosine by DNA 
sequencing 
With the help of next-generation sequencing technologies, one can now sequence 5hmC at a 
single base resolution using a variety of methods. The biggest challenge is being able to 
differentiate between all of the modified cytosine bases. SMRT (Single Molecule Real-Time) 
sequencing is able to identify 5hmC at a single nucleotide resolution, though it has a high rate 
of sequencing errors (Eid, Fehr et al. 2009). Two alternative methods have been created for 
the more common Illumina sequencing technology; Ox-BS-seq and TAB-seq.  
 
Oxidative Bisulfite Sequencing (Ox-BS-seq) builds upon a previously published method for 
investigating methylation – Reduced Representation Bisulfite Sequencing (RRBS) (Meissner, 
Gnirke et al. 2005). In short, RRBS uses the methylation insensitive restriction enzyme MspI 
to cleave DNA at CpG sequences, followed by treatment with sodium bisulfite, which 
converts unmodified cytosine bases to uracil, while leaving 5mC intact. This allows one to 
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look at methylation in areas rich in CpG islands. Recently it was found that traditional 
bisulfite (BS) sequencing is unable to distinguish between 5mC and 5hmC, and that the 
product of BS conversion of 5hmC is CMS (Figure 7), which has also been shown to stall 
DNA polymerases during PCR, and indicates that previous methylation analyses may 
underrepresent areas of dense hydroxymethylation (Huang, Pastor et al. 2010). To combat 
this Ox-Bs-Seq uses an additional oxidation step at the beginning of the protocol, where 
5hmC is oxidize to 5fC using Potassium Perruthenate (KRuO4), which reacts specifically 
with 5hmC and has no interaction with Cytosine or 5mC (Booth, Branco et al. 2012). The 
same protocol is then followed allowing one to look at 5hmC in a CpG context.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Effects of Sodium Bisulfite treatment on Cytosine, 5mC, and 5hmC (Huang, Pastor et al. 2012) 
 
 
Experiments using Ox-BS-seq have shown that 5mC and 5hmC have an inverse correlation 
with CpG density across CpG islands. Intra- and intergenic CpG islands have a higher 
amount of both 5mC and 5hmC than CpG islands overlapping transcription start sites (TSS). 
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LINE1 elements have also been shown to have ~5% 5hmC content, which could indicate the  
demethylation of specific repeat classes (Booth, Branco et al. 2012).  
Tet-Assisted Bisulfite Sequencing (TAB-seq) uses β-glucosyltransferase to tag 5hmC, 
protecting it during subsequent bisulfite conversion (Figure 8). After 5hmC is tagged and 
protected with a glucose molecule, TET proteins oxidize 5mC to 5caC. During bisulfite 
conversion, 5caC behaves as an umodified cytosine base would, while the 5hmC bases are 
protected from conversion, leading 5hmC to be read as cytosine, and 5caC to be read as 
thymine (Yu, Hon et al. 2012).  
 
 
Figure 8: TAB-seq flow chart (Fu and He 2012) 
 
Though Ox-BS-seq and TAB-seq are suitable methods for both single nucleotide resolution 
and quantifying relative abundance of 5hmC, there is one setback one must take into account 
for both methods. Both methods require one to run a BS-seq in parallel, as to be able to 
extract positional information on 5hmC, which considerably increases the costs of such 
experiments.  
 
High-resolution sequencing of 5hmC can also be achieved using DNA-modification-
dependent restriction enzymes coupled with sequencing. In a recently published method, 
5hmC was glycosylated and then subject to incubation with the restriction enzyme AbaSI, 
which specifically cleaves at a range of distances from the glycosylated 5hmC and doesn’t 
cleave 5mC or C (Sun, Jolyon et al. 2013). By mapping the cleaved ends of the fragments, 
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the exact location of 5hmC can be found (Wang, Guan et al. 2011). A similar method has 
also been published using MspI restriction enzyme (Section 2.3 – Sequence Specific 
Detection of 5-Hydroxymethylcytosine).  
 
1.5 Aims of the Thesis 
By studying the epigenetic context of 5hmC in MZ twins discordant for psoriasis, we aimed 
to acquire insight into the location of 5hmC distributed throughout the genome, and if the 
location of 5hmC had any implications in regards to psoriasis.  
 
The aims of this study were to: 
 
1. Quantify the amount of 5hmC found in CD4+ cells isolated from blood.  
2. Investigate the location of 5hmC on the human genome in a cohort of twins 
discordant for psoriasis. 
3. Perform a comparison of the hydroxymethylation profiles between the co-twins, and 
see if any differences can be associated with psoriasis.  
	   20	  
2 Methods and Materials 
2.1 ELISA – Quantification of 5hmC  
ELISA (Enzyme-linked immunosorbent assay) is a method of detecting an antigen in a 
solution by using an antibody against it. In short, antigens from a sample are bound to a 
surface, which is subject to incubation with an antibody recognizing the antigen. The 
antibody is linked to an enzyme, which when exposed to its substrate changes color. 
Therefore, a change in color shows the presence of the antigen, and using the depth of the 
color change and calculating absorbance, the amount of antigen present can be quantified. In 
this experiment, 5-hydroxymethylcytosine was detected and quantified using MethylFlash™ 
Hydroxymethylated DNA Quantification Kit (Epigentek). The protocol from the 
manufacturer was followed as described below (Figure 9): 
 
A dilution series was made using a supplied control DNA containing 5hmC; this creates a 
standard curve, which can be used to calculate the amount of 5hmC in the experimental 
sample. 200ng of purified CD4+ DNA and the standard curve DNA were bound to the assay 
wells by incubating the reaction in a binding buffer at 37°C for 90 minutes, followed by 
removing the binding solution and washing the wells. An antibody specific to 5hmC was 
added and incubated at room temperature for 1 hour, followed by washing and addition of the 
detection antibody. After an additional wash, an enhancer solution was added, followed by a 
developer solution. If 5hmC is detected, the developer solution will cause a color change 
from yellow to blue. Once color change is detected, a stop solution is added and the 
absorbance is read at 450nm on a microplate reader (Bio-Rad).  
 
Once the absorbance is read, the absolute amount of hydroxymethylated DNA in each 
experimental sample can be calculated in reference to the standard curve.  
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Figure 9 – Workflow of Epigentek MethylFlash Hydroxymethylated DNA Quantification Kit (Epigentek) 
	  
 	  
2.2 Hydroxymethylated Immunoprecipitation  
Immunoprecipitation is a technique that makes use of a specific antibody to bind a protein, 
which can then be separated from a solution. Hydroxymethylated Immunoprecipitation 
(hMeDIP) uses an antibody against 5hmC to recover fragments of DNA that contain 5hmC. 
The recovered DNA enriched in 5hmC can then be checked for enrichment using qPCR, and 
fold enrichment can be calculated. Immunoprecipitated DNA could also be sequenced to 
generate a genome-wide measure of 5hmC distribution. In this study, both the Active Motif 
hMeDIP Kit and Zymo Research Quest 5hmC DNA Enrichment Kits were used. The kits use 
different types of antibodies, but follow the same principal. Both kits follow the same DNA 
fragmentation procedure prior to starting the kit, as well as the same cleanup methods post 
elution.  
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2.2.1 hMeDIP using Zymo Research Quest 5hmC DNA Enrichment 
Kit 
Zymo Research’s Quest 5hmC DNA Enrichment Kit utilizes J-base binding protein (JBP1) 
for enrichment of DNA containing 5hmC. JBP1 is a protein that binds to the highly modified 
base β-glucosyl-5-hydroxymethyluracil, often referred to as the J-base and found in African 
trypanosomes. JBP1 binds to the β-glucosyl moiety of the J-base, as well as glucosyl moieties 
on other bases, such as glycosylated 5hmC.   
 
In the experiment, fragmented DNA is incubated with 5hmC Glucosyltransferase, which 
glycosylates 5hmC. Magnetic beads tagged with JBP1 are added to the solution containing 
glucose-tagged 5hmC and bind the DNA fragments containing 5hmC. After washing the 
beads, the DNA fragments enriched in 5hmC are eluted (Figure 10). The protocol was 
followed according to the manufacturers instructions, using 4µg of input DNA.  
 
Figure 10 – Workflow of Quest 5hmC DNA Enrichment Kit (From Zymo Research Corp.) 
 
To evaluate enrichment, a spike of 5hmC control DNA can be added to a sample as a positive 
control. The 5hmC control DNA is a mix of two plasmids chemically modified to contain 
either 5mC or 5hmC. The plasmids also differ in that the 5hmC-modified plasmid contains a 
KpnI restriction site. From these spiked plasmid templates, a 400bp PCR fragment containing 
the KpnI restriction site can be amplified. Successful enrichment is shown by cleavage of the 
400bp amplicon to 200bp fragments, which can be seen on a gel. A negative control reaction 
should be included where the protocol is followed, but 5hmC Glucosyltransferase is not 
added.  
 
2.2.2 Hydroxymethylated Immunoprecipitation using Active Motif 
hMeDIP Kit 
Instead of a glycosylation reaction prior to capture, as in the Zymo Research kit, Active 
Motif’s hMeDIP kit uses a highly specific purified 5-hydroxymethylcytidine antibody to 
capture DNA containing 5hmC. Briefly, fragmented DNA is incubated overnight in a 
solution containing a 5-hydroxymethylcytidine antibody. The next day, magnetic beads, 
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which bind to the 5-hydroxymethylcytidine antibody, are added to the solution and incubated 
for 2 hours. The DNA is then eluted from the beads, yielding DNA fragments enriched for 
5hmC (Figure 11). The protocol from the manufacturer was followed, using 1µg input DNA 
for all reactions. In this experiment, hMeDIP reactions were done using several different 
control DNA spikes (described below) as well as using a Rabbit IgG antibody for negative 
controls, allowing one to calculate enrichment after qPCR. 
 
For validation of the reaction, a spike of control DNA – an oligo containing either 5hmC, 
5mC or unmodified cytosines can be added to the reaction, and can be analyzed using qPCR 
using the provided APC locus primer mix. Because the APC locus is not hydroxymethylated 
in human DNA, enrichment shown in the qPCR should only be derived from the control 
DNA. Spikes of unmethylated and methylated DNA were also be added to reactions to ensure 
that the antibody does not immunoprecipitate those bases. A negative control reaction was 
also run using Rabbit IgG instead of the 5-hydroxymethylcytidine antibody, to control the 
specificity of the provided 5hmC antibody.  
 
Figure 11 – Workflow of Active Motif hMeDIP Kit (Active Motif, Inc.) 
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2.2.3 Purification of DNA after hMeDIP 
Following the hMeDIP protocols, the volume of DNA eluted was found to be too high, 
leaving the DNA at a concentration that is too low to be measured using the Qubit reagents 
(Appendix 5.1.1) and unsuitable for downstream applications. Eluted hMeDIP DNA was 
therefore concentrated to a lower volume by using either a QIAQuick spin column (Qiagen) 
or Ampure XP beads (Beckman Coulter) and eluted in 10 µl dH2O (Appendix 5.1.2). 
 
 
2.3 Oxidative Reduced Representation Bisulfite 
Sequencing 
Reduced Representation Bisulfite Sequencing is a method allowing for deep, selective 
sequencing of parts of the genome highly enriched for CpG islands, by using the methylation-
insensitive restriction enzyme MspI to generate fragments enriched with CpG dinucleotides at 
the ends (Meissner, Gnirke et al. 2005). The DNA is then treated with sodium bisulfite 
solution, which converts unmodified cytosine bases to thymine, so that when sequenced, an 
unmodified cytosine base is read as thymine, and 5mC is read as cytosine (Figure 12). This 
method was published before 5hmC was considered to be an epigenetic mark, and does not 
take into account that both 5mC and 5hmC are found as cytosine in sequencing data. 
(Matarese, Carrillo-de Santa Pau et al. 2011) 
 
Oxidative Reduced Representation Bisulfite Sequencing (ox-RRBS) starts with an oxidation 
step, converting 5hmC to 5fC, while leaving 5mC and C in their original states. With 
subsequent bisulfite conversion, both unmodified cytosine and 5fC are converted to thymine, 
while only 5mC is read as cytosine. By comparing ox-RRBS sequencing reads to RRBS 
reads, one can define where 5hmC is located in the genome.  
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Figure 12 – Diagram and table outlining RRBS and ox-RRBS methods (Booth, Branco et al. 2011) 
 
 
2.4 Sequence Specific Detection of 5-
hydroxymethylcytosine 
2.4.1 Preparation of control DNA from mouse brain 
Frozen whole mouse brain was obtained from John Arne Dahl at Rikshospitalet and genomic 
DNA isolated using a Qiagen DNEasy Blood & Tissue kit, which incubates tissue in a lysis 
buffer until homogenous, and then removes proteins and concentrates DNA by passing it 
through a spin column (Appendix 5.1.2) When protein contaminants were detected by UV 
spectroscopy (NanoDrop), the DNA was further cleaned up by Phenol: Chloroform treatment 
followed by EtOH precipitation (Appendix 5.1.2).  
 
2.4.2 Sequence and Locus Specific Detection of 5hmC using Zymo 
Research Quest 5hmC Detection Kit 
Similar to the hMeDIP protocol from Zymo Research (Section 2.2.2), this protocol starts with 
using 5hmC Glucosyltransferase, an enzyme that tags 5-hydroxymethylcytosine with a 
glucose moiety. A parallel reaction is run without glucosyltransferase treatment. Both of the 
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samples are then subject to treatment with MspI, a Glucosyl-5hmC Sensitive Restriction 
Endonuclease (GSRE), which cleaves at CCGG. MspI is a methylations insensitive enzyme; 
it will not cut sites that have a glycosylated 5hmC base, but will cut 5mC and unmodified 
cytosine bases (Figure 13). After MspI digestion, DNA was cleaned up and reconcentrated, 
rendering it usable for downstream applications. One can expect that the sample treated with 
the glucosyltransferase will have longer fragments than the untreated sample, as there will be 
fewer places for MspI to cut.  
 
 
Figure 13: Workflow of Quest-5hmC Detection Kit (Zymo Research Corp.) 
 
A positive control oligo with 5hmC in MspI cleavage sites is included in the kit and was used 
to check if the reaction worked correctly.  
 
2.4.3 Preparation for Sequencing 
Sequencing libraries were made using TruSeq DNA Sample Preparation (Illumina) reagents, 
in a protocol modified for low input. The purpose of this protocol was to prepare DNA 
fragments for sequencing by adding indexed adapters to each end of the DNA fragments.  
Reaction conditions can be found in Appendix 5.1.4.  
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First, the overhangs on the DNA fragments were converted to blunt ends using an End Repair 
Mix, which both removes the 3’ overhangs, and fills in the 5’ overhangs. To remove traces of 
enzymes and nucleotides, the DNA was cleaned using a DNA Clean & Concentrator – 5 
(Zymo Research) spin column, and eluted in 20µl Resuspension Buffer (RSB). Next, a single 
‘A’ nucleotide was added to the 3’ ends of the DNA fragments – preventing them from 
ligating to each other during adapter ligation and increasing ligation efficiency to the adapter 
molecules by introducing a single base overhang. Specific adapters with indexes were then 
ligated to the fragments, allowing them to hybridize onto a flow cell. A stop ligase mix was 
added to the solution to end the ligation process. Once again, the DNA fragments, now 122 
bp longer due to the addition of adapters, were cleaned up using a DNA Clean & 
Concentrator – 5 (Zymo Research) spin column and eluted in 12µl RSB.  
 
To remove adapter dimers and size-select DNA fragments for sequencing, the indexed DNA 
fragments were pooled and then run on a 2% TAE agarose gel for ca. 45 min at 100V. Two 
adjacent bands were then excised; the first band from 175-300 bp, the second from 300-766 
bp. Samples were split into two size fractions to allow more even sequence coverage on the 
Illumina HiSeq 2000: The clustering stage of sequencing relies on PCR, which favors 
amplification of smaller products, therefore combining fragments from the entire size range 
in a single clustering reaction would result in the vast majority of sequences being derived 
from the smallest fragments. DNA was extracted from the gel and cleaned using spin 
columns and reagents from Qiagen’s MinElute Gel Extraction Kit. The DNA was eluted from 
the spin column in 22.5µl of the supplied Elution Buffer. Next, the DNA was amplified in a 
PCR reaction using TruSeq reagents. The lowest possible number of PCR cycles was used to 
minimize PCR-induced bias and duplicate reads, in this case 13 cycles. Finally, the PCR 
reaction was cleaned up in a 1:1 Ampure XP bead cleanup, and DNA recovered in 15µl RSB. 
 
Quality control of the libraries was performed by checking the DNA concentration on the 
Qubit (Invitrogen), and checking that adapter dimers had been removed during the gel 
extraction step by running the samples on a BioAnalyzer High Sensitivity Chip (Agilent).  
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2.5 qPCR Validation of Experiments 
Quantitative (Real-Time) PCR is a method that simultaneously amplifies and quantifies DNA 
molecules. SYBR Green (Applied Biosystems), a fluorescent dye that binds to double 
stranded DNA was used in the reaction for quantification. It binds to dsDNA at the beginning 
of the reaction, and is released during the denaturing step. After the polymerization step when 
the PCR amplicon is generated, the dye binds to the amplicon, resulting in a net gain of 
fluorescence in the reaction, which is detected by the qPCR system (Figure 14).   
 
 
Figure 14: SYBR Green Dye Assay Chemistry (Applied Biosystems) 
 
qPCR was used to check for enrichment of 5hmC containing fragments at specific loci. There 
are currently very few loci known to be enriched in 5hmC, making primer design difficult. 
Primers used for qPCR are listed in Appendix 5.2.  
  
All qPCR reactions were run in triplicate on an ABI 7900 (Applied Biosystems) Real-Time 
PCR system. The absolute quantification method was used, allowing one to quantitate 
unknown samples based on a known quantity – a standard curve. The standard curve was in 
most cases made from DNA samples with the following concentrations: 20, 2, 0.2 and 0.02 
ng/µl. Following each qPCR reaction, a melting curve analysis was performed.  
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2.6 Sequencing 
Sequencing libraries were prepared such that compatible indexes were applied to samples of 
different insert sizes (either 150-300 bp or 300-766 bp), allowing these to be run together in a 
single lane. In total, two lanes of 100 bp paired end sequencing were run – one for each size 
range. The samples were clustered using TruSeq PE Cluster Kit v3-cBot-HS (Illumina), and 
sequenced using TruSeq SBS Kit v3  (200 cycles; Illumina) on a HiSeq 2000 instrument 
(Illumina). Sequencing was performed by the Norwegian Sequencing Centre 
(www.sequencing.uio.no). 
 
2.7 Analysis of Sequencing Results 
Image analysis and base calling were performed using Illumina’s RTA software version 1.12. 
Reads were filtered to remove those with low base call quality using Illumina’s default 
chastity criteria. In addition, due to the lower quality of bases at the 3’ end of the sequence 
reads (Figure 29), reads were trimmed to 50bp using fastx-trimmer from the FASTX-toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/). Reads from the two size fractions 30-180 bp and 
180-646 bp (lengths after removal of adapter sequences) were combined for further analysis. 
 
Genome sequences for mouse (mm10) and human (hg19) were downloaded from Ensembl 
(http://www.ensembl.org/info/data/ftp/index.html). Sequence reads were aligned to the 
appropriate genome index using bwa (http://bio-bwa.sourceforge.net). A summary of the 
number of reads and mapping results are given in Table 1 (Section 3.5). 
 
To identify CpG sites with 5hmC, it is necessary to identify locations with read map 
differences between the samples with +/- glycosylation reaction. To do this, we used MACS 
(Model-based analysis for ChIP-seq; http://liulab.dfci.harvard.edu/MACS/), with + 
glycosylation sample as treatment and -glycosylation sample as control. MACS identifies 
peaks that are significantly different between the two samples, and thus MspI sites which 
contain 5hmC. A summary of the number of significant peaks is shown in Figure 31 (Section 
3.5). 
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3 Results 
3.1 ELISA  
ELISA experiments were run using both control DNA from mouse brain, as well as twin 
DNA isolated from CD4+ T-cells. Mouse brain DNA was chosen as a positive control as it is 
known to have a higher than average 5hmC content.  
 
The first few ELISA experiments were run with a standard curve made from the 
recommended values from the kit of 10.0, 5.0, 2.0, 1.0 and 0.5 ng/µl. This resulted in a non-
linear curve, mostly from the sample with 10ng of hydroxymethylated DNA. Later 
experiments used a standard curve with concentrations of 1.0, 0.5, 0.2, 0.1 and 0.05ng/µl, 
resulting in a linear curve, which was used to extrapolate the amount of 5hmC in each DNA 
sample in ng, and from there calculate the percentage of 5hmC in the DNA samples.  
 
Figure 15: 200ng of CD4+ DNA from 4 twin pairs, and 200ng of mouse brain DNA was run in triplicate. DNA 
samples are shown along the X-axis, while % Hydroxymethylcytosine is on the Y-axis. The percent of 5-
hydroxymethylcytosine of each sample and standard error were calculated from triplicate values. Twin pairs are 
shown in the same color. The healthy twin is denoted by a circular mark, the affected twin by a triangle.  
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The mouse brain DNA, which served as a positive control was determined to have 
approximately 0.15% 5hmC in the sample, while the CD4+ DNA, which varied within twin 
samples, was shown to have 0.02-0.06% 5hmC content. (Figure 15)  
 
Significant differences (t-test p<0.05) were detected within three of the discordant twin pairs 
tested, though the second twin pair was not found to be significantly different (p=0.603). 
Therefore, we could detect global differences in 5hmC content within the twin pairs. 
However, there was no consistent relationship between disease state and hydroxymethylation 
level. Given the low number of twin pairs, it is only possible to draw minimal conclusions 
from the data.  
 
Despite the low concentrations of 5hmC in the CD4+ DNA, we felt justified in proceeding 
with further experiments to examine 5hmC using more comprehensive assays.  
 
3.2 Hydroxymethylated DNA Immunoprecipitation 
All hMeDIP experiments were done using what we believe to be DNA from mouse brain 
(C57BL/6) provided by Arne Klungland at Rikshospitalet, and human genomic DNA 
(gDNA) from an anonymous donor (P-152) used as control DNA at the Department of 
Medical Genetics. The mouse brain served as a positive control in addition to the control 
oligos found in the respective hMeDIP kits. However, upon completion of the experiments 
detailed below, we were informed that we had mistakenly been given rat brain DNA. 
Nonetheless, further experiments were performed with genuine mouse brain DNA (see 
below) and produced identical results. 
 
The lack of previously identified loci enriched in 5hmC made designing amplicons for qPCR 
validation a difficult task. At the time of running the experiment, only one publication was 
found with information in regards to specific loci in human tissues enriched in 5hmC. The 
regions identified to be the most enriched throughout various human tissues included IGF2, 
H19, and the HOXA cluster (Nestor, Ottaviano et al. 2012). Despite these regions showing 
considerably lower levels of enrichment in blood, we were forced to proceed in designing 
qPCR amplicons in these regions due to the lack of other sources of information. For human 
samples, one locus at the IGF2 region and three loci from H19 were chosen as likely positive 
controls, where qPCR amplicons were designed. Tex19.1 was used to make a mouse qPCR 
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primer set for the mouse control samples, as it has also been previously identified as 
containing 5hmC (Nestor, Ruzov et al. 2010). GAPDH was used as a negative control for 
both species. After performing a melting curve analysis to check for primer efficiency, we 
found that the IGF2 primer set amplified in the non-template control (NTC) wells, while the 
other primer pairs amplified only in wells with DNA. The IGF2 primer set was discarded for 
further experiments, and only the H19 primer sets were used. The first Tex19.1 primer set 
designed failed to amplify, presumably due to the template DNA originating from the wrong 
species. Another set was therefore designed and fortuitously amplified correctly.  
 
3.2.1 Zymo Research Quest 5hmC Enrichment 
hMeDIP experiments were repeated several times using the Zymo Research Quest-5hmC 
Enrichment kit. The first run using 1µg mouse (in fact, rat) DNA did not lead to any pull 
down, confirmed by Qubit measurements and lack of amplification by qPCR. This led us to 
repeat the experiment with 4µg input of mouse (rat) DNA in parallel with 4µg, 3µg, 2µg and 
1µg human gDNA. Once again, there was no measurable enrichment from checking DNA 
concentration on the Qubit or qPCR.  
 
To make sure the kit was performing correctly, we ran a control hMeDIP using 1µg human 
DNA along with 200ng provided control DNA from the kit. A reaction was also run in 
parallel using the same input with no spike-in. After enrichment, the captured DNA was 
amplified and subject to KpnI treatment. Because the control oligo has KpnI recognition sites, 
a gel can be run with the samples and there will be a visible difference in size when 
comparing the treated and untreated samples. A 1% TBE gel was made and the samples were 
run at 100V for 35 minutes.  
                       Lane 1 Lane 3        Lane 5   Lane 7                  
 
 
 
                      400bp 
                      200bp 
 
 
Figure 16: Control Zymo hMeDIP. Lane 1- 100bp Ladder, Lane 3 - Enriched control oligo, no KpnI treatment, 
Lane 5 - Enriched control oligo, KpnI treated, Lane 7 - Human gDNA sample, no spike or KpnI treatment 
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In Figure 16 we can see visible bands in both of the lanes from the hMeDIP with the control 
oligo spike, - a band at 400bp in Lane 3 for the untreated sample, and a band at 200bp in 
Lane 5, but no visible band in the lane without the control spike. If the hMeDIP had pulled 
down significant amounts of 5hmC-enriched fragments from the gDNA sample, there would 
be a visible band or smear at approx. 500bp (the size of the sheared input DNA) in lane 7. 
There is an obvious enrichment of the control fragment from the hMeDIP reaction, as shown 
by the visible bands in both Lane 3 and 5, and by the difference in sizes between the sample 
treated with KpnI and the untreated sample. Because there was no cleanup reaction after 
running the PCR and subsequent restriction enzyme digest, we see leftover primer dimers in 
both samples at the bottom of the gel.  
 
These results led us to conclude that while the kit was able to pull down the spiked-in control 
plasmid sequences, we were unable to pull down sufficient gDNA fragments enriched in 
5hmC. This led us to try another type of kit before looking into other methods.  
 
After receiving genuine mouse brain from which to extract fresh DNA (Section 3.3), we 
repeated the experiment in hope of a positive result, but once again we found no measurable 
enrichment of DNA using the Qubit instrument. Using the pulled-down DNA as template, we 
also ran a qPCR assay to detect potential 5hmC enrichment at positive control loci using the 
primer sequences supplied to us from Zymo for the Sequence Specific Detection of 5hmC 
(Section 3.3), but were unable to see any enrichment.  
 
3.2.2 Active Motif hMeDIP 
Because the Zymo hMeDIP kit didn’t lead to any positive results, we decided to try a 
different kit, which uses an antibody directly specific to 5hmC. Once again, mouse brain (in 
fact, rat) DNA served as a positive control.  
 
We first ran a reaction using 1µg (the maximum input) rat DNA, which yielded no 
enrichment, so a reaction was set up with 1µg (the maximum input) rat DNA, 1µg human 
gDNA, and 1µg human gDNA spiked with 50pg of the control oligo from the kit. Again, 
there was no obvious enrichment from Qubit measurements, though we were able to see 
enrichment from the spiked control, confirming that the kit was able to enrich it’s own 
control oligo.  
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In order to calculate enrichment levels at various loci, we set up a new set of IP 
(Immunoprecipitation) reactions, this time including a negative control using rabbit IgG. 
Human gDNA samples were spiked with three different control oligos, the first being an 
oligo where the cytosine bases were all hydroxymethylated, the second with only methylated 
cytosine, and the third with unmodified cytosines (unDNA). A negative control sample was 
also included in the experiment, comprised of human gDNA and the 5hmC control DNA, but 
was subject to Rabbit IgG instead of the 5-hydroxymethylcytidine antibody during 
immunoprecipitation. The control DNA samples can all be amplified during qPCR using a 
primer set that amplifies the human APC locus, which contains only unmodified cytosines. 
The APC locus has never been shown to be methylated in human gDNA, so the only 
expected enrichment should come from the spiked sample. A rat hMeDIP was also run in 
parallel to the human hMeDIP – 1µg of rat DNA alongside an identical sample, which was 
subject to rabbit IgG instead of the 5-hydroxymethylcytidine antibody. No control DNA was 
added to the rat reactions, as the primers that amplify it are made for human gDNA. Once 
again, we saw no significant signs of enrichment from the unspiked samples from both Qubit 
measurements and the qPCR.  
 
 
 
Figure 17: qPCR assay measuring enrichment of spiked human gDNA samples from the Active Motif hMeDIP 
kit – relative enrichment on the Y-axis represents the amount of IP DNA recovered from each spiked sample 
normalized against the negative control rabbit IgG reaction. Primers used in the control experiment are listed 
along the X-axis, where Active Motif refers to the APC primer set supplied with the kit. Error bars represent 
standard error. UnDNA spike refers to oligo without any modified cytosine bases.  
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Figure 18: Enrichment of rat brain DNA samples from Active Motif hMeDIP kit – relative enrichment on the Y-
axis represents the amount of IP DNA recovered from each sample normalized against the negative control 
Rabbit IgG reaction. qPCR products are shown along the X-axis. Error bars represent standard error.  
 
Relative enrichment of each spiked reaction was calculated from qPCR data. As expected, we 
see significant enrichment from the gDNA sample spiked with 5hmC control DNA (t-test 
p<0.05), but we also see similar enrichment from the samples containing methylated and 
unmodified spikes (Figure 17). Both the H19_DMR and GAPDH loci also show insignificant 
levels of enrichment from all of the spiked samples, though these levels are much lower than 
from the Active Motif primer set, which amplified the APC locus. There should be an 
increase in enrichment in spiked samples as compared to genomic DNA alone, but the only 
amplification we saw was from the spiked samples, none in the gDNA samples.  
 
The rat brain DNA hMeDIP showed similar results to the human gDNA hMeDIP, though 
there is no spike-in control to compare them to. The relative enrichment levels at both the 
Tex19.1 and GAPDH loci are comparable to the enrichment levels of H19_DMR and GAPDH 
in the human hMeDIP with control DNA. Enrichment at Tex19.1 and GAPDH was calculated 
to be insignificant using a t-test (Figure 18).    
 
 Before moving on to a different method, we tried concentrating our DNA samples to 12µl 
and 10µl using both Qiagen spin columns and Ampure XP beads to hopefully see some 
enrichment. Unfortunately we were still unable to detect any DNA on the Qubit. In a final 
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effort to understand why the hMeDIP reactions weren’t working correctly, we ran a gel to 
check for DNA degradation. As seen in the gel image below (Figure 19), no obvious 
degradation is visible. Although disappointing, we were nonetheless forced to concede that 
the commercial hMeDIP kits were not sensitive and or efficient enough to successfully pull 
down 5hmC from DNA other than artificial oligos. We therefore decided to focus our efforts 
on a different method.  
 
          Lane 1        Lane 3           Lane 6 
 
Figure 19: 8% TBE Agarose Gel, 100V, 30 min. Lanes 1&3: Mouse brain DNA supplied by Rikshospitalet. 
Lane 6: 1 KB ladder 
 
3.3 Sequence Specific Detection of 
Hydroxymethylcytosine 
3.3.1 DNA Isolation 
Having exhausted our supply of mouse brain (in fact, rat) DNA for use as a positive control, 
we were required to isolate more. To this end, we obtained whole mouse brain from John 
Arne Dahl at Rikshospitalet, from which we isolated DNA. This material was used as a 
positive control for subsequent experiments.  
 
After isolation of DNA from mouse brain using the DNEasy Blood & Tissue Kit (Qiagen), 
the purity of the DNA was checked on the NanoDrop (Thermo Scientific). A 260/280 ratio of 
~1.8 and a 260/230 ratio of ~2.2 is expected for DNA samples. Contamination from proteins, 
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which absorb at 270nm, can impact the 260/280 ratio, while phenol absorbs at 230 and 
270nm, so it can impact both the 260/280 ratio and 260/230 ratio. In Figure 20, the 260/280 
ratio is much lower than expected, indicating the presence of a protein contaminant. 
Removing it required a phenol:chloroform extraction followed by EtOH precipitation.  
 
 
Figure 20: NanoDrop result before Phenol: Chloroform cleanup; notable protein contamination.  
 
 
Figure 21: NanoDrop result after Phenol: Chloroform cleanup, no obvious sources of contamination. 
 
Post phenol:chloroform extraction, one can see in Figure 21 that the 260/280 ratio has 
normalized, and is closer to 1.8.  We determined that the isolated DNA was cleaned up and 
potential contaminants had been removed, and proceeded on to the next step, detecting 5hmC 
in a locus-specific context.  
 
3.3.2 Detection of 5-hydroxymethylcytosine using Zymo Quest-
5hmC Detection Kit  
The first reaction we ran was comprised of only the control oligo supplied from the kit, as to 
not waste valuable mouse brain DNA. 50ng of control oligo was incubated with 5hmC 
Glucosyltransferase, and a reaction was ran in parallel without the enzyme. Next, both 
samples were subject to a restriction enzyme digest by MspI, and subsequently cleaned up 
using a spin column. 5hmC glucosyltransferase tags 5hmC with a glucose moiety, and blocks 
MspI from digestion when the inner cytosine at the recognition site (CCGG) is glycosylated.   
 
When checking for enrichment of 5hmC at a particular locus using qPCR, differences in 
amplification efficiencies will be seen between the glycosylated and unglycosylated samples 
and indicate the presence of 5hmC. As seen in Figure 22, the negative control sample (-
control) indicates a level of 0% hydroxymethylation at the locus, and a no treatment sample 
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(no 5hmC glucosyltransferase or MspI treatment) represents complete hydroxymethylation at 
the interrogation site. The experimental sample should lie between these two values.  
 
Figure 22: Detection of 5hmC by qPCR (Zymo Research Corp.) 
 
We ran a qPCR using the provided qPCR primers on the control oligo, a 90bp oligo with one 
MspI recognition site with the inner cytosine at the recognition site being hydroxymethylated. 
An untreated sample was used calculate 100% hydroxymethylation and the negative control 
used to calculate 0% hydroxymethylation. The experimental sample was then calculated to 
have 136% hydroxymethylation at the interrogation site (Figure 23). 
 
 
Figure 23: Locus specific detection of 5hmC using Zymo control oligo and control primer set.                           
% Hydroxymethylcytosine detected on the Y-axis. Error bar represents standard deviation.  
 
The mouse brain sample was then subject to incubation with first 5hmC Glucosyltransferase, 
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the glucosyltransferase was also run (-glycosylation reaction). As expected, we were able to 
detect DNA at concentrations of 16.6 ng/µl (+ glycosylation) and 17.9 ng/µl  
(-glucosoylation). The variation is most likely due to the usage of spin columns to remove 
leftover enzyme and buffers from the reaction. 
 
 We received the sequences of four qPCR primers (two sets of positive controls and two sets 
of negative controls) used by Zymo Research to detect enrichment at specified loci in mouse 
brain. A qPCR was then run in the same fashion as with the control oligo in hopes of seeing 
enrichment in our brain tissue samples, which would allow us to move on to library 
preparation of our samples for sequencing.  
 
 
 
Figure 24: Enrichment of 5hmC in Mouse brain using qPCR primers provided from Zymo Research. Primer sets 
used are represented on the X-axis (Mouse Brain +1, -1, +2, -2), and % Hydroxymethylcytosine on Y-axis. 
Error bars represent standard error.  
 
 
We can see from Figure 24 that we were indeed able to detect significant levels of 
enrichment when comparing the percent 5hmC at the positive and negative control loci (t-
test, p > 0.05). Just as in our qPCR reaction with the control oligo, we detected 
hydroxymethylation values above 100% for each amplicon.  However, because we saw a 
significant difference in enrichment between the positive and negative loci, we concluded 
that the reaction had worked correctly, and we continued with the same protocol this time 
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using CD4+ DNA from three sets of control co-twins (six DNA samples altogether), yielding 
12 human DNA samples and 2 mouse DNA samples ready for library preparation.  
 
3.3.3 Library Preparation 
As we were able to show the enrichment of 5hmC for the mouse control samples using the 
Quest-5hmC Detection Kit (Zymo), we proceeded with library preparation for sequencing. 
100ng of each sample was subject to library preparation using TruSeq DNA reagents as 
outlined in section 2.4.4. Each sample was ligated to a specific adapter. Directly before the 
size-separation step, the +glycosylation and –glycosylation samples were pooled to avoid the 
introduction of false-positive differences caused by slight differences in size selection. Two 
bands from a 2% TAE Agarose gel were excised; one from 150-300bp, and the second from 
300-766bp (Figures 25 & 26). The most intense signals, which appear as “bands” in the gel-
like image, indicate repetitive elements cut by the MspI enzyme. 
 
 
                                      Lane 1            Lane 3           Lane 5 
 
 
 
        766bp 
 
 
 
        300bp 
 
         
        150bp                  
 
 
 
 
Figure 25: Image of 2% TBE gel before size selection, Lanes  
1 and 3 contain Low Molecular Weight Ladder (NEB),  
and Lane 3 contains the sample.  
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                                         Lane 1         Lane 3          Lane 5 
 
 
 
        766bp 
 
        300bp  
 
        150bp 
 
 
           
 
 
                    Figure 26: Image of 2% TBE gel after excision of 150-300bp  
      and 300-766bp fragments. Contents of the lanes are the  
      same as Figure 25 
 
Proper size selection assures that correctly sized fragments are available for sequencing, as 
well as removing primer dimers, which will interfere with sequencing, and amplify in the 
subsequent PCR reaction. While optimizing the library preparation, we were also able to 
reduce the number of PCR cycles from 13 to 12, with the aim of minimizing PCR-induced 
bias during sequencing.  
 
After PCR and the following Ampure XP bead cleanup, finished libraries were run on the 
Bioanalyzer 2100 using High Sensitivity chips and reagents to check for primer dimer 
contamination, and that the libraries were the correct sizes. In Figures 27 and 28, we can see 
that the libraries are of the correct sizes, and there is no visible peak at 120bp, which would 
indicate primer dimer contamination.  
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      Figure 27: BioAnalyzer image of pooled + and – glycosylation reactions for twin 211181, with a spread 
from roughly 150-300bp, with peaks at 200 and 262bp. BP is represented on the X-axis, and Fluorescence Units 
on the Y-axis.  
 
 
Figure 28: BioAnalyzer image of pooled + and – glycosylation reactions for twin 211181, with a spread from 
roughly 300-766bp with a large peak at 333bp and a lesser peak at 377bp. X- and Y-axes are the same as above.  	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3.4 Sequencing 
3.4.1 Quality of the Sequenced Reads 
A FASTQ file, where the quality for each base of a read is scored, was provided for all of the 
sequenced samples. The quality scores can be used to exclude low quality reads from 
analysis. As the samples were sequenced in a 100bp paired-end reaction, quality scores are 
provided for each member of the pair. Although all the sequenced samples passed quality 
control, we ended up with fewer reads than expected, and qualities that declined more rapidly 
than is normally seen. A quality score of 20 (indicative of a 1 in 100 chance of error) is 
considered acceptable, while a quality score above 28 is considered very good. A quality 
score below 20 is considered insufficient.  
 
We can see from the Per Base Sequence Quality graph (Figure 29) that the quality of the 
reads decreases quite rapidly after position 70 on the graph, and while a decrease of quality at 
the end of a read is normally seen when using Illumina technology, this is a much more rapid 
decrease than usually seen.  
 
 
Figure 29:  Per Base Sequence Quality of Twin Sample 14511, insert size 150-300bp fragments, read 1. The 
range of quality scores across all bases at each position in the FASTQ file is shown. Quality scores are plotted 
on the Y-axis, and read position on the X-axis. Yellow boxes represent the IQR (25-75%) range of the reads, 
and the whiskers represent 10% and 90%. The red and blue lines display the median and mean of the quality 
values.  
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The distribution of quality scores for all reads should also be examined to see the spread of 
the quality of reads from the sample, and potentially allow us to exclude samples with too 
low quality from analysis. Ideally we would see a narrow peak at 38, indicating that all of the 
reads have a high quality. Instead, we see in Figure 30 that the spread of our quality scores is 
quite broad, with a peak at quality score 29. Large portions of our reads have a quality score 
below 20, which is the bottom range of a read having acceptable quality. During analysis, we 
excluded low quality reads and trimmed our reads to 50bp to remove the low quality portions 
of the reads (Section 2.7).  
 
Figure 30: Per Sequence Quality Score over all sequences. Average quality score is plotted on the X-axis and 
number of reads on the Y-axis. 
 
 
3.5 Sequencing Analysis 
After the reads were trimmed and aligned to the respective reference genomes, we were able 
to see the type of coverage we received from sequencing. An overview of the mapped reads 
for each sequenced sample is seen in Figure 31, and we can see that a significant portion of 
our reads are mapping uniquely to the reference genomes. Interestingly, we saw a trend of 
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our treatment samples having on average a 20% decrease in uniquely mapped reads as 
compared to our control samples. Full details of the reads can be found in Appendix 5.3, 
Table 4.  
 
 
Figure 31: Overview of mapped reads from sequencing. Samples are listed on the X-axis, and percentage of 
reads that were unmapped, mapped uniquely and mapped ambiguously are shown on the Y-axis. Treatment 
refers to samples treated with both 5hmC glucosyltransferase and MspI, and Control refers to samples only 
treated with MspI.  
 
After alignment, MACS was used to identify significant peaks. While MACS called a large 
number of significant peaks for each sample, there were only a few that were differentially 
called between the control and treatment samples (Table 1).   
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Sample Number of peaks Different +/- (FDR 5%) 
Mouse 3338 0 
14511 9010 5 
14512 12579 10 
21181 4823 0 
21182 7814 5 
211701 8972 0 
211702 6302 5 
Table 1: Summary of significant peaks called using MACS for each sequenced sample. Twin samples are 
identified through ID-numbers. Sample name in column one, number of peaks called by MACS in column two 
and number of peaks with significant differences between the + glycosylation and - glycosylation control in 
column 3.  
 
3.5.1 Mouse Brain Control 
Because the experimental sample treated with 5hmC glucosyltransferase blocked MspI from 
cutting at the recognition site when 5hmC is present, we expected to see a difference between 
the experimental and control samples. While the treated sample will show coverage at an area 
where 5hmC is present, the control sample will lack coverage, due to MspI cleavage. 
Alternatively, the 5hmC glucosyltransferase treated samples are too large, and in that case we 
would only identify the control samples. Another possible outcome from sequencing is 
opposite of the aforementioned scenario, where two MspI recognition sites are close together 
the control samples are too small (minimum size for sequencing is 30 bp) for sequencing, and 
we would only see coverage from the treated sample.  
 
Though we were unable to identify any significant peaks in the mouse control samples, in 
Figure 32 we can see nonetheless see two such examples identified by visual inspection 
showing differences in coverage at MspI recognition sites. In Cdk2, MspI was unable to cut at 
the recognition site in the glycosylated sample, resulting in two distinct peaks. The control 
sample has two corresponding regions with a lack of coverage. It is likely that increased 
sequencing depth would result in a lack of visible difference at this site. We can also see that 
the identified regions are located in a CpG island, thus showing that we have positively 
identified the presence of 5hmC in our sample.  We expected to find that most of the regions 
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identified would have no visible differences between the control and experimental samples, 
an example of such is seen in Figure 33 at Atp5e.  
 
 
 
Figure 32: Screenshot from UCSC Genome Browser (genome.ucsc.edu) at Cdk2 in the mouse genome. From 
top to bottom, the tracks included in the image are the experimental sample treated with 5hmC 
Glucosyltransferase, the control sample, MspI recognition sites from REBASE, gene tracks from UCSC, RefSeq 
and Ensembl, and at the bottom, CpG islands.  
 
 
Figure 33: Screenshot from UCSC Genome Browser at Atp5e in the mouse genome. Tracks are the same as in 
Figure 31.  
 
3.5.2 Control Twin Samples 
In addition to mouse brain DNA, the Quest-sequencing approach was also applied to 
genomic DNA isolated from CD4+ cells from 3 pairs of human monozygotic twins. These 
twin pairs were not discordant for any disease phenotype, but represent control individuals. 
As in the mouse samples, we expected to detect sites of 5hmC based on the differences 
between glycosylated and non-glycosylated samples. While we were unable to identify any 
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significant peaks in the mouse samples, our human samples had a number of significant 
peaks. Below in Figure 34 we see such a region in REXO1L1, which codes for RNA 
Exonuclease 1-homolog (S. cerivisiae)-like 1.In the middle of the figure, in the promoter 
region of the gene, there is a region with significant enrichment in the treatment sample, with 
no corresponding enrichment in the control sample, showing the presence of 5hmC.  While 
there is a visible difference in enrichment between the peaks on the right-hand side of the 
figure, it was not deemed significant.  
 
 
Figure 34: Screenshot of REXO1L1 coding region from UCSC Genome Browser. The tracks in ascending order 
are; control sample, treatment sample, CpG Islands, RefSeq Genes, Repetitive Elements from Repeat Masker 
and MspI sites from REBASE. 
 
We expected to see significant differences in enrichment in CpG islands, due to the nature of 
MspI cleaving at CpG sequences, which tend to overlap with promoter regions in genes. This 
was not the case, as most of the significant peaks mapped to non-coding regions of the 
genome, but we were able to see regions with good coverage. One such region is shown in 
Figure 35 – the IFG2 coding region, which was used as one of our positive control loci for 
our hMeDIP qPCR experiments. While we were unable to detect any significant differences 
between the control and experimental samples in this region, we do see that we have good 
coverage from the sequencing. We did not see any enrichment in the region of our IGF2 
qPCR amplicon (shown in red on image) used as a positive control for our hMeDIP 
experiments. This could be due to lack of sequencing depth, but a different region with MspI 
sites that show enrichment from our sequencing results can be used to make a better positive 
control for future experiments.   
Scale
chr8:
SINE
LINE
LTR
DNA
Simple
Low Complexity
Satellite
RNA
Other
Unknown
10 kb hg19
86,799,000 86,800,000 86,801,000 86,802,000 86,803,000 86,804,000 86,805,000 86,806,000 86,807,000 86,808,000 86,809,000 86,810,000 86,811,000 86,812,000 86,813,000 86,814,000 86,815,000 86,816,000 86,817,000 86,818,000 86,819,000 86,820,000 86,821,000
Extended tag pileup from MACS version 1.4.2 20120305
Extended tag pileup from MACS version 1.4.2 20120305
CpG Islands (Islands < 300 Bases are Light Green)
RefSeq Genes
UCSC Genes (RefSeq, UniProt, CCDS, Rfam, tRNAs & Comparative Genomics)
Repeating Elements by RepeatMasker
Restriction Enzymes from REBASE
CpG: 130 CpG: 130
REXO1L2P REXO1L2P
REXO1L1
14511_control_all
209 _
1 _
14511_treat_all
208 _
1 _
	  49	  
Figure 35: Screenshot of IGF2 coding region from UCSC Genome Browser. Tracks are the same as in Figure 
34. The red bar on the bottom left of the image corresponds to our qPCR amplicon used as a positive control in 
our hMeDIP experiments.  
 
We were only able to detect significant peaks in four of our twin samples, and only one of the 
twin pairs. All four of the twin samples had significant peaks at LINC00601, three had a 
significant peak at PWRN1, and two shared a significant peak at DGKB. The only significant 
peak found in common between a twin pair was at LINC00601.  
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4 Discussion 
4.1 ELISA 
The detection of 5hmC by ELISA was considered an essential prerequisite to this project, as 
proceeding to the other methods would have been futile if no 5hmC was detectable in human 
DNA isolated from CD4+ cells. Encouragingly, we were able to detect 5hmC in both the 
mouse brain and human twin CD4+ samples. It was interesting to note that the differences in 
hydroxymethylation in the diseased and sick twins were not significant. This suggests that 
gross differences in 5hmC levels do not underlie the disease phenotype. However, it remains 
possible that locus-specific differences could be important, the detection of which requires a 
more sensitive and specific assay. 
 
The values we found for 5hmC concentration in mouse brain tissue and CD4+ DNA differed 
from published results. While we found mouse brain to have a 0.15% 5hmC content, and 
CD4+ DNA to have a 0.02-0.06% 5hmC content, previous studies have identified 0.6% 
overall hydroxymethylation in brain tissue (Kriaucionis and Heintz 2009), and about 1000 
times lower in blood (Nestor, Ottaviano et al. 2012). Our experimentally determined value 
for 5hmC content in brain tissue was about four times lower than the previously determined 
amount, while our CD4+ DNA had over 100 times the amount of the published values. This 
discrepancy is most likely due to the assay type used. Other reported values of 5hmC in a 
tissue or blood specific context have mainly been quantified using Mass Spectrometry, which 
is much more sensitive than an ELISA assay. Another possible source of error while 
performing the ELISA experiment could have been overdevelopment during the detection 
step of the protocol, where the directions ambiguously stated to wait until the solution had 
turned ‘medium blue’ to add the stop solution.  
 
4.2 hMeDIP 
Although there have been positive results in identifying 5hmC enriched loci using hMeDIP 
published (Nestor, Ottaviano et al. 2012), we were unable to obtain positive results from our 
hMeDIP experiments. This was most surprising for our mouse brain samples, as we expected 
to see significant enrichment due to the higher concentrations of 5hmC than our other 
samples. While there has been seen a global reduction of 5hmC in cell cultures (Nestor, 
Ottaviano et al. 2012), our control DNA was isolated directly from brain tissue, and shouldn’t 
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be subject to this phenomenon. In the future, if further experiments were to be done using the 
isolated CD4+ DNA twin material from cell cultures, then this would need to be taken into 
account.  
 
A likely possibility for the lack of enrichment in the hMeDIP could be due to problems with 
the antibody used. Both the Zymo Research and Active Motif hMeDIP kits were both able to 
enrich their own positive control oligos, which have 19 hydroxymethylated cytosines in a 90 
bp oligo and many hydroxymethylated cytosines in an unspecified plasmid control, 
respectively. It is reasonable to assume that the density and high percentage of 5hmC in these 
artificial control constructs led to positive results from the immunoprecipitations. 5hmC isn’t 
found in these quantities or densities in our experimental DNA samples, which most likely 
had an effect on the lack of results we saw. In the case of the 5-hydroxymethylcytidine 
antibody from the Active Motif kit, which also pulled down significant amounts of the non-
hydroxymethylated control oligos, the antibody may be rather non-specific, though this leads 
to even more confusion as to why we were unable to detect any enrichment. 
 
Our qPCR experiments were also unable to detect enrichment at the loci we chose to make 
qPCR amplicons. We may have had more success with different loci, but we were unable to 
find other enriched loci at the time of the experiment. Other possible regions in human DNA 
that we could have used for human controls include the HOXA cluster and TEX14 (Nestor, 
Ottaviano et al. 2012). As 5hmC is further studied, more regions should be identified as being 
5hmC enriched, and should represent suitable positive controls for such qPCR reactions 
 
It is of notable interest that both the IGF2 and H19 genes were both previously identified as 
being enriched for 5hmC, as they are reciprocally imprinted and expressed almost exclusively 
from the paternal and maternal chromosomes, respectively, during both zygote and postnatal 
development (Kaffer, Grinberg et al. 2001).  As 5hmC also plays an important role in 
development, coinciding with global demethylation, further research could provide insight 
into the role of 5hmC and imprinting. Interestingly our qPCR experiments were unable to 
detect any enrichment at loci. This is a cause for concern, as these loci were supposed to be 
used as positive controls, though we may have been able to see significant differences 
between the treatment and control samples if we had greater sequencing depth.  
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After finishing the hMeDIP experiments we were informed (by a technician at 
Rikshospitalet) that we had actually received rat brain DNA instead of mouse brain DNA. 
While the GAPDH qPCR primer set created for mouse mapped to the rat genome, the 
Tex19.1 primer set did not. Interestingly, we saw amplification when making a standard 
curves for the qPCR experiments using the mouse Tex19.1 primer, due to conserved 
sequences. Rat brain DNA has been shown to have similar amounts of 5hmC in comparison 
to human and mouse brain tissue (Wang, Guan et al. 2011), so one could expect that the 
DNA isolated from rat brain should also have worked with our hMeDIP kits. The hMeDIP 
procedure was also repeated using the DNA isolated from mouse brain in our lab, but we 
failed to detect enrichment by qPCR.  
 
4.3 Sequence Specific Detection of 5hmC 
As we were unable to show any enrichment of 5hmC using our qPCR primer sets, we 
contacted Zymo Research and received from them the sequences of four primer sets that they 
had previously tested and showed detection of 5hmC in mouse brain tissue. The first primer 
set, comprised of a positive and negative control both mapped to PAX9, which codes for a 
transcription factor active in early embryo development in mice.  The second set, also 
contained positive and negative control primers, but mapped to noncoding regions of the 
genome. Most likely it had been previously determined that the MspI sites in the positive 
control primers had a 5hmC base at the MspI recognition site, and the negative control 
primers had no hydroxymethylation at the recognition site, making them suitable for 
detecting the presence of 5hmC at these sites.    
 
While we were able to show that our glycosylation reactions had worked, and had blocked 
MspI from cutting at hydroxymethylated cytosine residues at the recognition site, we were 
puzzled as to why we had values that showed over 100% hydroxymethylation at specified 
loci, both using the control oligo as well as our experimental samples. The protocol from the 
kit states that from a qPCR reaction, a level of 100% hydroxymethylation is established by 
the no treatment control DNA, and 0% hydroxymethylation established by the negative 
control, and the glycosylated sample should therefore lie in between those values. We see in 
Figure 22 that the glycosylated sample has a slightly lower Cp value than the glycosylated 
sample, meaning that the producers of the kit also should have seen values of over 100% 
hydroxymethylation in the glycosylated sample. We are unsure as to why this is the case, but 
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a possibility is the treatment of the sample DNA during the protocol, specifically being 
passed over spin columns during cleanup, results in a greater loss of the untreated sample.  
  
4.4 Sequencing 
We assume that the quality of the reads was low due to the fact that all samples were treated 
with MspI, leading to all our reads starting with the same sequence. This sequence bias in the 
initial cycles can lead to a loss of fidelity in cluster identification, thereby causing a reduction 
in the number of reads (Krueger, Andrews et al. 2011). Interestingly, this phenomenon hasn’t 
been previously seen in sequencing of RRBS samples (also cut with MspI) in our lab.  To 
mitigate this problem, a PhiX (viral genome) control can be added to the libraries during 
clustering, shifting the base composition of the library and adding diversity to the base 
composition of the library for future experiments.   
 
4.5 Sequencing Analysis 
While we were able to identify a distinctive number of peaks in each sample, we saw at most 
10 significant peaks in a specific sample. The most reasonable explanation for the lack of 
significant peaks is low sequencing depth. If the experiment were to be repeated with the 
addition of a PhiX control during cluster generation, we can expect to have higher quality 
sequences, and therefore a higher sequencing depth. It is also of interest that our treatment 
samples had a decrease in uniquely mapped reads in comparison to the control samples, as 
the treatment samples had on average, more reads than the control samples. The control 
samples were cut more often than the treatment with MspI leading to shorter fragments, so a 
possibility is that the shorter fragments were more successful in mapping to the reference 
genome.  
 
When investigating the locations of the significant peaks in our human samples, we found 
that all of them had a significant peak at LINC00601, a long interspersed non-coding RNA. 
Three of the four samples with significant peaks also called a significant peak at PWRN1, a 
non-protein coding RNA in the Prader-Willi region. Both of these peaks are found in 
repetitive regions, and interestingly enough LINE1 elements have previously been found to 
contain 5% 5hmC content (Booth, Branco et al. 2012), and these results could further 
strengthen the hypothesis that 5hmC may be involve in demethylation of specific repeat 
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classes. Locations of other significant peaks called by MACS can be found in Table 5 in 
Appendix 5.3.  
 
Due to the lack of depth from sequencing, we were unable to extract more positional 
information from the peaks, though if the samples were to be re-sequenced with PhiX, we can 
assume that many more significant peaks would be found in CpG islands near coding regions.  
 
4.6 Conclusion 
We were able to show the presence of 5hmC from DNA isolated from both mouse brain 
tissue and CD4+ cells, though there was a discrepancy in that the mouse brain sample had a 
lower amount than previously published, while the CD4+ DNA samples had a higher amount 
than previously seen. Again, this is most likely due to sensitivity of the assay used.  
 
While we had great difficulty in finding a method for investigating 5hmC at a single base 
resolution, we can conclude that we were able to do so using Zymo’s Quest 5hmC Detection 
Kit in combination with appropriate size selection of the digested DNA, and high throughput 
sequencing. In the future this combination of reactions could be optimized and become a new 
method for detecting 5hmC, and different restriction enzymes can be used for different 
coverage. We were able to identify a number of regions that had significant differences 
between the control and treatment samples. While many of these regions were found in 
repetitive sequences and noncoding regions, they were identified in multiple samples. Further 
sequencing is required to fully validate the method.  
 
4.7 Further Research 
Unfortunately due to time constraints, we were unable to investigate 5hmC in the discordant 
twin pairs. As we were able to identify 5hmC in both the mouse and twin samples, as well as 
see similarities in the twin samples, the next logical step would be to repeat the experiment, 
with the inclusion of the PhiX control during clustering, and using the discordant twins, 
hopefully identify differences in them that have implications in disease causing genes in 
psoriasis. Additionally, positional data of 5hmC could be compared to data from previous 
methylation analyses to see if any cytosines that were previously identified as being 
methylated are in fact hydroxymethylated.  
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We experienced unexpected difficulties in the project, most specifically getting the hMeDIP 
reaction to yield enriched 5hmC fragments. This was particularly surprising, given that the 
reagents used were commercially available kits sold specifically for this purpose. As 5hmC is 
a relatively new DNA modification to study, in the future there will hopefully be a number of 
more robust methods conceived. As it was most likely the low concentration of 5hmC in our 
sample DNA which led our hMeDIP reactions to fail, it would be advantageous for future 
research if a method was developed to take into account the minute amount of 5hmC found in 
DNA, especially blood and cell extracts.   
 
While the mechanism for how 5mC is converted to 5hmC has been explained, the question of 
what regulatory role, if any, 5hmC performs in the genome still exists. It has been shown that 
an increase of 5hmC during development coincides with global demethylation (Wu and 
Zhang 2011), though it is still not understood exactly what role 5hmC has during 
development. Similarly, its function in gene expression has yet to be elucidated. The TET 
enzymes responsible for the conversion of 5mC to 5hmC have been shown to have different 
roles in other biological processes (Tan and Manley 2009), but it is still unclear as to whether 
or not they are functionally redundant in regards to 5hmC.  
 
Lastly, the reason for the high concentration of 5hmC in Purkinjie neurons is still unknown. 
High levels of 5hmC in frontal lobe tissue has been shown to be correlated to gene 
expression, and further research on the topic could provide insight into neurodevelopment.  
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5 Appendix 
5.1 Protocols 
5.1.1 DNA Quantification 
Qubit 
Qubit is a fluorometric method of quantifying DNA concentration.  
1. Prepare a working solution of 199 µl Qubit dsDNA HS Buffer and 1 µl Qubit dsDNA 
HS Reagent per sample. 
2. Add 190 µl of the working solution to the tubes used for standards, 199 µl for each 
sample tube.  
3. Add 10 µl of each Qubit standard or 1 µl sample to the appropriate tubes.  
4. Vortex 2-3 seconds to mix.  
5. Incubate samples at room temperature for 2 minutes.  
6. Calibrate Qubit Fluorometer using standards.  
7. Insert sample tubes one by one into Qubit Fluorometer and read off DNA 
concentration.  
 
Bioanalyzer 
The Bioanalyzer (Agilent) is a microfluidics platform that allows quantification, sizing, and 
quality control of nucleic acid samples. In this project, both DNA High Sensitivity and DNA 
1000 chips were used. High sensitivity chips were used for quality control of libraries, and 
DNA 1000 chips were used for sizing of genomic DNA.  
 
Fragmentation of DNA 
Prior to the hMeDIP protocol, DNA must be fragmented into ca. 500 bp in length; otherwise 
extremely long fragments of DNA will the pulled down, making the subsequent sequencing 
costly and of low resolution. DNA was fragmented using a Covaris S220 sonicator. First, 
DNA is brought up to 130 µl using 1X TE Buffer, and then sonicated for 80 seconds at a 10% 
duty factor, 140-peak power, 200 cycles per burst. Post-sonication, the sample was 
reconcentrated using a QIAQuick PCR Purification (Qiagen) column and eluted in 30 µl 
(Appendix 5.1.2). To ensure that the DNA has been correctly fragmented, samples were run 
on a BioAnalyzer (Agilent) DNA 1000 Chip. 
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5.1.2 DNA Isolation, Cleanup and Concentration 
Isolation of DNA from Mouse Brain 
DNA from mouse brain was prepared using DNeasy Blood & Tissue kit from Qiagen. 
Previously dissected brain from a mouse were brought to room temperature, and cut up into 
smaller 25 mg pieces. The pieces of brain were then incubated in a lysis solution for 8 hours 
at 56°C until the solution was homogenic.  The solution was then passed over a provided spin 
column, and yielded 30µg DNA. The DNA concentration and purity of the sample was 
checked on the Qubit Fluorometer (Invitrogen) and NanoDrop (Thermo Scientific), 
respectively (Appendix 5.1.1).  
 
Phenol: Chloroform Cleanup of DNA 
When NanoDrop measurements indicated an excess of protein left over from the column-
based cleanup using the DNeasy Blood & Tissue Kit (Qiagen), the DNA was subjected to 
additional cleanup by Phenol: Chloroform Extraction (Chomczynski and Sacchi 2006). 
Briefly, an equal volume of Phenol: Chloroform is added to the DNA solution, vortexed, and 
spun in a centrifuge for 2 minutes at top speed. The top aqueous layer containing DNA is 
transferred over into a fresh tube, while the protein-containing interphase and organic layers 
are discarded. The procedure is then repeated using pure Chloroform, and again, the aqueous 
phase containing DNA is kept, while the other phases are discarded.  
 
To reconcentrate DNA, a simple Ethanol precipitation protocol is followed. Along with 0.1 
volumes of NaOAc, 3 volumes of chilled (-20°C) 100% EtOH are added to the aqueous 
phase from the Phenol: Chloroform cleanup. The solution is spun in a centrifuge at 6°C for 
30 minutes, and then a DNA pellet should be visible. The supernatant is removed, and the 
pellet is washed with chilled (-20°C) 70% EtOH. The solution is once again spun in a 
centrifuge at top speed for 15 minutes, 4°C. Once finished, the supernatant is removed, and 
the pellet is air-dried on the lab bench. Once all traces of alcohol are gone, the pellet is 
resuspended in 50µl TE Buffer. The quality and concentration of the DNA can then again be 
verified on the NanoDrop and Qubit (Appendix 5.1.1).  
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Ampure XP Cleanup 
AmpureXP beads were used in either a 1:1 or 1.8:1 bead to DNA solution ratio, depending on 
the required outcome. A 1.8:1 ratio will remove all products less than 100bp from the 
solution, while a 1:1 ratio removes fragments around 200bp and lower.  
1. Add Ampure XP beads to DNA solution in desired ratio. 
2. Incubate the solution for 15 minutes at room temperature. 
3. Place tube on magnetic stand and incubate for 5 minutes.  
4. Remove supernatant without disturbing the bead pellet. 
5. Add 200 µl 80% EtOH, incubate 30 seconds, and remove supernatant. 
6. Repeat wash step.  
7. Air dry pellet to remove traces of ethanol for 7-8 minutes 
8. Remove from magnetic rack and resuspend beads in desired volume.  
9. Incubate solution 2 minutes, room temperature.  
10. Place tube back on magnetic rack and incubate for 5 minutes or until solution is clear.  
11. Transfer supernatant containing DNA into fresh tube.  
 
5.1.3 PCR & qPCR Reactions 
 
Standard qPCR Reaction 
Master Mix: 
iTaq Universal SYBR Green Supermix: 5 µl 
10X Primer Mix (10 pmol/µl) (F+R):  1 µl 
ddH20:      2 µl 
DNA Standard/Sample:   2 µl 
    Total:  10 µl 
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Amplification Conditions 
50°C – 2 min 
95°C – 10 min 
95°C – 15s             
60°C – 10s 40 cycles         
95°C – 15s 
60°C – 15s Melting Curve Analysis 
95°C – 15s             
 
 
Zymo Quest 5hmC Enrichment Kit  
Reaction setup: 
5hmC enriched DNA:    1µl  
Control Primers:    1µl 
QuestTaq Premix:    10µl 
dH20:      8µl 
    Total:  20µl 
 
Amplification Conditions 
95°C – 3 min 
95°C – 30s      
59°C – 30s          28 Cycles 
72°C – 30s 
72°C – 1 min 
4°C – hold 
 
KpnI Enzyme Cut 
NEB 1 Buffer:     1µl 
Amplified DNA from PCR:   5µl  
BSA:      1µl 
KpnI Enzyme:     1µl 
dH2O:      2µl 
    Total:  10µl 
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5.1.4 Illumina Library Preparation 
End Repair 
Set up reaction on ice; incubate at 30C for 30 min: 
100ng 5hmC DNA:  x µl 
Resuspension Buffer (RSB): x µl 
End Repair Mix (ERP): 20 µl 
  Total:  50 µl 
 
Adenylate 3’ Ends 
Set up reaction on ice; incubate at 37C for 30 min, followed by 70C for 5 minutes. Cool on 
bench to room temperature, and then place on ice.  
DNA from End Repair: 17.5 µl 
A-tailing Mix (ATL):   12.5 µl 
  Total:  30 µl 
 
Ligate Adapters 
Set up reaction on ice; incubate at 30C for 10 minutes.  
Adenylated DNA:  30 µl 
RSB:    2.5 µl 
Ligase Mix (LIG):  2.5 µl 
1:4 Diluted Adapters:  2.5 µl 
  Total:  37.5 µl 
 
PCR Amplification 
Set up reaction on ice and amplify according to specified conditions.  
DNA from Adapter Ligation:  20 µl 
TruSeq PCR primer cocktail:  5 µl 
TruSeq PCR master mix:  25 µl 
  Total:   50 µl 
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Amplification Conditions 
98C – 30s 
98C – 10s 
60C – 30s   13 cycles  
72C – 30s 
72C – 5 min 
 
5.2 Primers 
Table 1: qPCR primers - Human Oligo	  Name	   Sequence	  5’à3’	   Amplicon	  Size	  H19_DMR_A1	  FWD	   GATCTCGGCCCTAGTGTGAA	   188bp	  H19_DMR_A1	  REV	   GTGATGTGTGAGCCTGCACT	  H19_genic_4	  FWD	   GCCAGCTACACCTCCGTTG	   137bp	  H19_genic_4	  REV	   AGCTAGGGCTGGAAAGAAGG	  IFG2_genic_1	  FWD	   CATGAAATTTGGGGGTTCC	   112bp	  IGF2_genic_1	  REV	   GGGAGTTCTGGGGTAGGAAG	  H19_promoter_2	  FWD	   CCTGGAATTCTCCAAAGACG	   115bp	  H19_promoter_2	  REV	   AGTGGTCTGGGAGGGAGAAG	  GADPH	  FWD	   CGGCTACTAGCGGTTTTACG	   189bp	  GADPH	  REV	   AAGAAGATGCGGCTGACTGT	  
 
Table 2: qPCR primers – Mouse Oligo	  Name	   Sequence	  5’à3’	   Amplicon	  Size	  Tex19.1	  FWD	   AAAATGGGCCACCCACATCTC	   184bp	  Tex19.1	  REV	   CCACTGGCCCTTGGACCAGAC	  GADPH	  FWD	   CCTGCGACTTCAACAGCAACTCCCA	   135bp	  GADPH	  REV	   TGAGGTCCACCACCCTGTTGCTGTA	  
 
Table 3: qPCR Primers from Zymo for Mouse Brain 
Oligo Name Sequence 5’à3’ Amplicon Size 
Mouse Brain +1 FWD GCAGTTTCGTCTCAGCATCC 223 bp 
Mouse Brain +1 REV GCAGAAGCGGTCACAGAATG 
Mouse Brain +2 FWD ATGGGTTCTCTGGCTCGATT 191 bp 
Mouse Brain +2 REV CTGGCTGATTTTTGGAAGGA 
Mouse Brain -1 FWD CTTGTCCAAGTGGCGTTTTC 218 bp 
Mouse Brain -1 FWD CACTGCACTGCCTCTGTCAA 
Mouse Brain -2 FWD GGCATTGGGATGTGAACAGT 207 bp 
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Mouse Brain -2 REV CCCACCTCACCTAAAATCAGTG 
 
5.3 Sequencing Data 
Table 4: Overview of Mapped Reads from Sequencing. Treatment reactions are denoted with 
a suffix of 1, while control reactions have a suffix of 2.  Reads	   Unmapped	   Mapping	  uniquely	   Mapping	  ambiguously	   Total	  Mouse_1	   2521996	  (25%)	   6338995	  (62.8%)	   1227873	  (12.2%)	   10088864	  Mouse_2	   789215	  (7.9%)	   7802009	  (78.2%)	   1384474	  (13.9%)	   9975698	  14511_1	   2501516	  (28.9%)	   5508094	  (63.6%)	   656696	  (7.6%)	   8666306	  14511_2	   532938	  (9.6%)	   4506496	  (81%)	   524820	  (9.4%)	   5564254	  14512_1	   2159998	  (25.1%)	   5775229	  (67.1%)	   669691	  (7.8%)	   8604918	  14512_2	   450999	  (8.7%)	   4293034	  (83.1%)	   423253	  (8.2%)	   5167286	  211181_1	   4917059	  (32.5%)	   9185952	  (60.8%)	   1009303	  (6.7%)	   15112314	  211181_2	   436104	  (11.1%)	   3181015	  (80.9%)	   316845	  (8.1%)	   3933964	  211182_1	   2491774	  (22.3%)	   7809323	  (69.9%)	   877921	  (7.9%)	   11179018	  211182_2	   715289	  (10%)	   5817984	  (81.6%)	   595921	  (8.4%)	   7129194	  211701_1	   2930641	  (27.3%)	   7025473	  (65.5%)	   769604	  (7.2%)	   10725718	  211701_2	   606819	  (9.6%)	   5169886	  (81.5%)	   564007	  (8.9%)	   6340712	  211702_1	   3541944	  (36.7%)	   5525601	  (57.2%)	   596389	  (6.2%)	   9663934	  211702_2	   813594	  (9.6%)	   6967312	  (82.1%)	   708344	  (8.3%)	   8489250	  
 
Table 5: Locations of peaks identified to be significant by MACS 
Sample chr start end length fold_enrichment FDR(%) 
14511 chr1 228767450 228767608 159 7.84 0 
14511 chr10 128106460 128106604 145 2.49 0 
14511 chr15 24768644 24768768 125 6.58 0 
14511 chr7 14728958 14729096 139 9.48 0 
14511 chr8 86809573 86809730 158 33.14 0 
14512 chr10 128106462 128106602 141 5.96 0 
14512 chr12 84068408 84068731 324 808.7 0 
14512 chr16 32169678 32169834 157 592.89 0 
14512 chr19 36788825 36788998 174 6.63 0 
14512 chr19 36791011 36791230 220 29.22 0 
14512 chr21 9720851 9721001 151 114.73 0 
14512 chr3 185671850 185672097 248 16.9 0 
14512 chr5 102476275 102476578 304 126.48 0 
14512 chr6 131863139 131863296 158 9.6 0 
14512 chr7 1077150 1077295 146 330.43 0 
21182 chr10 128106452 128106612 161 3.44 0 
21182 chr11 68243257 68243801 545 32.82 0 
21182 chr11 112005739 112005874 136 2.84 0 
21182 chr15 24768640 24768788 149 2.95 0 
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21182 chrY 4277181 4277506 326 10.7 0 
211702 chr10 128106442 128106622 181 2.17 0 
211702 chr15 24768635 24768798 164 2.34 0 
211702 chr16 71197186 71197322 137 220.91 0 
211702 chr3 15790547 15790915 369 648.94 0 
211702 chr7 14728953 14729096 144 2.25 0 
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